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INTRODUCTION
Restless legs syndrome (RLS) is a chronic sensorimotor 
disorder [1-4]. RLS can either be primary or secondary. 
Primary or idiopathic RLS, diagnosed when clinical 
conditions responsible for secondary forms are 
excluded by laboratory and clinical examinations, 
accounts for about 70 -80% of all RLS cases [1,5]. 
Among secondary or symptomatic forms, several conditions 
such as iron deficiency anemia, uremia, pregnancy, 
polyneuropathy and type 2 diabetes mellitus have been 
implicated in association with RLS [6-11]. RLS has 
recently been characterized by The International Restless 
Legs Syndrome Study Group (IRLSSG) as a clinical 
syndrome presenting as a combination of intense desire 
to move the limbs associated with paresthesias/dysesthesias; 
motor restlessness; exacerbation of symptoms with 
inactivity and relief by activity; and a nocturnal worsening 
in the symptom [12]. According to the Western data, it 
affects approximately 7-11.5% of the adult population 
and is found to be higher in women than in men. The 
intensity of sensory and motor symptoms generally 
tends to increase with advancing age. Alcoholics, smokers 
and selective serotonin reuptake inhibitor (SSRI) users 
as well as patients suffering from neuropathy are more 
likely to have RLS [2, 13-16]. Diabetes mellitus is a lifelong 
disease and a common cause of sensorimotor polyneu-
ropathy [13]. However, previous studies on RLS in 
diabetic neuropathy yielded conflicting results with a 
prevalence rate ranging from 8.8 to 27%, not significantly 
different even from controls in some studies [11, 17-18]. 
Poor glycemic control with RLS may also impact the 
associated consequences of diabetes mellitus including 
sleep quality, sleep cycle alterations, fatigue, and 
depression [19]. Norma G et al reported that diabetic 
people at risk for RLS were at increased risk for obstructive 
sleep apnea and insomnia-sleep problems often 
reported in diabetes [19]. Montplasir et al reported 
significant association between RLS and Periodic Limb 
Movements during Sleep (PLMS) during sleep or while 
INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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awake [20]. However, there is paucity of local data in this 
regard. We hypothesized that patients with type 2 
diabetes mellitus will show a high frequency of RLS.  
Therefore, we sought to determine the frequency of RLS 
in subjects with type 2 diabetes mellitus and its associ-
ated factors especially sleep disturbances, daytime 
time functioning  and PLMS. with non-adherence to 
AEDs and help in taking possible measures to improve 
antiepileptic drug compliance and prevent conse-
quences of uncontrolled seizures. The prevalence of 
epilepsy in Pakistan is about 9.99/1000.
METHODS
Patient selection
For this study, 120 consecutive subjects with type 2 
diabetes mellitus who attended the diabetes clinic of 
Jinnah Medical Dental College Hospital, Karachi from 
July 2009 to July 2010 were recruited. Ethical approval 
for the study was taken from local ethics review 
committee of the hospital. The non-diabetic group 
consisted of 54 consecutive patients who attended the 
medical outpatient clinics for some seasonal illness 
during the study period with no sign/symptom of any 
chronic disease. We included all the subjects who were 
30 years old or above, irrespective of the gender. We 
excluded all the patients who were known to have (or 
were being treated for) anemia, chronic liver disease, 
thyroid dysfunction, uremia and non-diabetic polyneu-
ropathy. Similarly, pregnant women were excluded from 
the study as RLS is already expected to be more prevalent 
in this set of population. Patients who had a language 
barrier were also excluded to minimize the biases in 
clinical findings and ensure the authenticity of information. 
All the participants provided an informed consent.
General Protocol
Records were reviewed and patients were interviewed 
using a closed ended questionnaire regarding their 
demographic aspects, past medical history, family 
history and use of medications. In particular, we 
inquired about the clinical conditions which support 
RLS (such as iron-deficiency anemia, hypothyroidism, 
uremia, and rheumatoid arthritis) and about the drugs 
which could possibly worsen RLS symptoms 
(antidepressants or antipsychotics) or rather improve 
RLS symptoms (dopaminergic agents, benzodiazepines, 
and anticonvulsants such as gabapentin, carbamazepine, 
oxcarbazepine, and valproic acid). Moreover, both 
diabetic and non-diabetic subjects were specifically 
asked for: (1) disturbance of sleep (2) daytime sleepiness 
(3) daytime dysfunction; and (4) presence of PLMS. Sleep 
disturbance was defined as difficulty in falling asleep 
and awakening. Daytime sleepiness was assessed by 
Epworth Sleepiness Scale (ESS) which is a validated 
tool. A score of >10 was indicative of excessive 
daytime sleepiness. [13] Patients were considered to 
have daytime dysfunctioning when they have a subjective 
complain about it. Presence of PLMS as reported by the 
bed partner or close family member was ascertained as 
described in the literature i.e. periodic jerky movements 
causing flexion of the ankle, knee, or hip; occasionally 
accompanied by arousals from sleep, leading to sleep 
fragmentation and excessive daytime sleepiness [18]. 
RLS Protocol
In all the study subjects, a neurologist confirmed the 
presence of RLS using the criteria defined by the Inter-
national Restless Legs Syndrome Study Group (IRLSSG) 
[12]. Only the patients who fulfilled all 4 criteria were 
considered affected by RLS and were further asked 
about the frequency, duration and intensity of the 
symptoms. Presence of RLS symptoms in first-degree 
relatives was established in both diabetic and non-
diabetic subjects.
 
Laboratory Data
Laboratory data was obtained at the time of interview 
for complete blood count, creatinine, random and 
fasting blood glucose in all subjects and for serum 
ferritin and glycosylated hemoglobin (HbA1c) in 79 and 
152 subjects respectively.
Evaluation of polyneuropathy
Distal sensory function was examined bilaterally using 
Semmes-Weinstein (SW) filaments as recommended by 
the World Health Organization and International Diabetes 
Federation for screening peripheral neuropathy in 
diabetic subjects [21]. The dorsal surface of the foot and 
the heel was tested in a random manner on 10 prede-
termined sites [21-22] with the filament pressed perpen-
dicularly, for 1 second, and pressure enough to bend 
the filament. Patient’s response was noted on the basis 
of yes/no option. Those patients who were able to 
perceive at less than 6 points were considered to have 
neuropathy [21].
Statistical Analysis
Sample size estimation: A sample size of at least 175 
was required to estimate the proportion of RLS among 
diabetics, however there is no literature available in our 
region assuming 10-15% prevalence in the regional 
population along with 80 percent power, 0.05 significance 
level, 5 percent bond on error, and 5% adjustment for 
non-response rate. As previously reported by Rozina S 
et al, RLS was seen in around 10% of the general 
population.[7] Data was entered and analyzed using 
Statistical Package Social Sciences (SPSS) version 
19.0. Initially descriptive statistics and frequencies and 
proportions were generated. Continuous variables were 
analyzed by t– test and categorical by chi-square or 
Fisher exact, where appropriate.  Later stepwise multi-
variable logistic regression was done to identify factors 
related with RLS among diabetics.
RESULTS
General characteristics of the diabetic and non-diabetic 
subjects are presented in Table 1. Diabetic subjects 
were comparably elder as compared to the non-diabetic 
subjects. Also, there was a slight preponderance of 
male gender in the diabetic subjects. Presence of sleep 
disorders, PLMS and RLS, family history of diabetes 
mellitus and RLS, and higher glycemic indices were 
significantly frequent among diabetic subjects. Only 
34% of the diabetic subjects had a value of HbA1c < 
7%. Most of the patients (94%) were taking oral hypo-
glycemic agents, the rest were on insulin therapy. PLMS 
were reported by 32 (26.7%) diabetics’ subjects only; 
of whom 21(65%) subjects had RLS. Sixty seven of the 
120 subjects with type 2 diabetes mellitus (55.8%) 
were diagnosed as having RLS (p < 0.05). Among 
these subjects, 28/67 (41.8%) had diabetes for < 
5years, 26/67 (38.8%) for >10 years, while the rest of 
them (13/67; 19.4%) had diabetes for 5-10 years. The 
laboratory parameters of RLS subjects revealed higher 
values for the glycemic indices including random and 
fasting blood sugar; and HbA1c level (Table 2). Among 
RLS subjects, none reported a positive family history of 
any sleep disorder which was in contrast to 4 (3.7%) of 
the non-RLS subjects. Among the subjects who did not 
fulfill the RLS criteria (n;53) the individual RLS like 
complains were evaluated. Unpleasant sensation in the 
legs with urge to move them was reported in 42.8%, 
worsening during inactivity or rest in 25.6%, relieved by 
activity in 18.1% while nocturnal worsening was 
reported by 22.4% of non- RLS subjects. Among RLS 
subjects, the majority of the subjects were using over-
the-counter analgesics (59/67; 88%). In univariate 
analysis, female gender, increasing age, clinical 
evidence of neuropathy, disturbance of sleep, daytime 
sleepiness, and impaired daytime functioning appeared 
as predictors of presence of RLS (Table 3). However, 
only advancing age, impaired daytime functioning and 
clinical evidence of neuropathy appeared as the predictors 
of RLS in multivariate analysis (Table 4). The multivariable 
analysis showed that having impaired daytime functioning 
due to sleep disorder was 47 times more associated 
with RLS adjusting for other covariates (adjusted Odds 
Ratio (OR) 47; 95% CI 10.3-217). Likewise, odds of 
having RLS among those with an evidence of neuropathy 
were 15 times more than those without neuropathy 
(adjusted OR= 15, 95% CI = 3.8-58). Every one year 
increase in age showed a 20% increase in risk of having 
RLS after adjusting other variables (Adjusted OR= 1.2, 
95% CI = 1.1-1.3). Interestingly, despite the high 
prevalence reported from the subcontinent, none of the 
non-diabetic subject suffered from either RLS or PLMS. 
To our surprise, none of the subjects who were 
diagnosed as RLS was ever asked by their physician for 
symptoms or diagnosis of RLS prior to this study.
DISCUSSION
The reported prevalence of RLS in general population by 
Western countries ranges between 5-15% [23] whereas 
data from Asian countries has reported a lower prevalence 
(1.5% in Japan [24], 1% in Singapore [25], 3.19% in 
Turkey [26]). Recently, higher prevalence rate i.e. 9.71% 
[27] has been reported by a Turkish study but their study 
population included subjects aged 40 years and above. 
Population based studies have found higher prevalence 
rates of RLS among subjects with advanced age, 
increased body mass index, smoking and diabetes 
mellitus [28,29]. Such varied differences in ranges might 
be due to the reason that some have heterogeneity in 
study design, study population and sample size. With 
no local data in this regard from Pakistan, this is the 
first Pakistani study confirming significant association 
between RLS and type 2 diabetes mellitus. The 
frequency of RLS in our diabetic subjects (55.8%) is 
significantly higher than compared to the international 
literature. Merlino et al diagnosed the RLS on the basis 
of International RLS Study Group criteria and reported a 
prevalence of 17.7% in their study population of 
diabetic subjects [4]. Lopes et al reported a comparatively 
higher frequency of RLS in 27% of the diabetic subjects 
[18], which is still lower than the frequency we found in 
our cohort. Peripheral neuropathy has been postulated 
to be associated with the pathogenesis of RLS. Qu S 
and Jensen et al have hypothesized that RLS in diabetic 
subjects could be due to the concurrence of decreased 
inhibitory dopaminergic control on the dorsal horns of 
the spinal gray matter [30-31] with the excitatory nociceptive 
inputs due to the peripheral neuropathy [32]. Various 
clinical studies have reported a significant association 
between RLS and polyneuropathy [8,33,34]. However, 
Skomro et al reported an insignificant association 
between RLS and diabetic polyneuropathy (p-value: 
0.78) [11]. In our study, odds of having RLS among 
those with an evidence of neuropathy were 15 times 
more than those without neuropathy (adjusted OR= 
15, 95% CI = 3.8-58). Diabetic subjects who were 
affected by RLS described their symptoms as an urge to 
move their limbs while those who had clinical evidence 
of neuropathy described their symptoms as pain, 
electric, or burning (pricking) sensations. This is in 
accordance with previous results shown by Winkelmann 
et al and Merlino et al [4, 35] A part from neuropathy, iron 
deficiency anemia is a well known contributor towards 
symptomatic form of RLS.[10] Our iron studies have 
shown insignificant association between RLS/diabetic+ 
subjects and iron studies which was in accordance with 
results demonstrated by previous studies [4, 11] thus 
further  pointing towards a lack of association. However, 
more clinic-pathological studies are needed to further 
verify this hypothesis. Significant number of RLS 
patients in our study reported sleep disturbance with 
daytime sleepiness and impaired daytime functioning 
which was consistent with results from previous studies 
on diabetic subjects. We found sleep disturbance to be 
associated with polyneuropathy and RLS. Similar correlation 
has been demonstrated by previous other studies [11, 14, 
36-37]. Our study has shown a significant association 
between RLS and PLMS as the majority of the PLMS 
patients were suffering from RLS too. In addition to 
diabetes, studies have also reported a significant association 
of RLS with diseases such as hypertension which could 
be due to concomitant sleep disturbances in such 
patients [38-41]. Advancing age and polyneuropathy have 
been shown to be associated with an increased preva-
lence of RLS [18,28]. The multivariate analysis established 
this association in our subjects as well (Table 2). A large 
number of our non-RLS subjects were those who 
suffered from a combination of symptoms included in 
the IRLSSG diagnostic criteria but they however, failed 
to meet all 4 criteria to be defined as RLS. We assume 
that these patients might be a potential case of RLS 
and may be defined as possible or probable RLS later. 
We propose that this criterion might be revised to take 
into account these large number of potential RLS 
patients so that early diagnosis and thus early identification 
of risk factors and their treatment might help them to 
enjoy a better quality of life. Interestingly, none of the 
non-diabetic subject suffered from either RLS or PLMS. 
Most importantly, none of our RLS subjects were ever 
asked by their physician for symptoms or diagnosis of 
RLS prior to this study. This may be because of the poor 
awareness of RLS among physicians as well.
LIMITATIONS
Our study was a single centered study so results cannot 
be generalized over the whole population. Ideally the 
patients who are suspected to have neuropathy by SW 
monofilament testing should undergo a standard nerve 
conduction study –the gold standard for the confirmation 
of neuropathy. Also, PLMS needs to be diagnosed with 
standard polysomnography.
STRENGTHS
This will be the first study from Pakistan which has 
addressed the frequency of RLS and its association with 
diabetes mellitus. Therefore, the results of this study 
are important as they provide the insight into this 
important and potentially treatable medical disorder in 
the local perspective. In addition to results shown 
above, our study has also shown the utility of SW mono-
filament in screening for the presence of sensory 
neuropathy. This is important in view of World Health 
Organization (WHO) report which has stated that 32% 
of the Pakistani population lives below poverty line. 
Hence, nerve conduction study (NCS/EMG) is not an 
economically pliable tool for the diagnosis of sensory 
neuropathy in our general community. So, SW filament 
utility has again come up in our study as a useful tool.
CONCLUSION
RLS is a common problem among patients with type 2 
diabetes mellitus and is associated with increasing age, 
peripheral neuropathy and impaired day time functioning. 
Its diagnosis is often delayed because of poor recognition 
by the physicians. Early diagnosis may result in 
improved quality of life of these patients. Considering a 
substantial number of subjects with one or more symptoms 
suggestive of RLS in the non-RLS group, further studies 
with larger sample size are needed to establish the 
importance of individual symptoms to guide the investi-
gation and the therapy in this sub-set of patients.
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ABSTRACT
Objective: To determine the frequency of restless legs syndrome (RLS) and its associated factors in patients with type 
2 diabetes mellitus. Design and Methods: It was single centered, cross-sectional study done with convenient 
sampling. The study population comprised 174 subjects (120 diabetics and 54 non-diabetics). Participants were 
recruited from the Diabetes clinic of Jinnah Medical College Hospital, Karachi. The relevant clinical and laboratory 
parameters were obtained by clinical history and chart review. Multivariable logistic regression was done to identify the 
factors of RLS among diabetics. Results: Using the International RLS Study Group (IRLSSG) criteria, RLS was identified 
only in 67(55.8%) subjects from the diabetic group. The mean age of RLS subjects was 56±8 years as compared to 
46±8 years in the non-RLS subjects. Forty percent (26/67) of the diabetic/RLS+ subjects had diabetes for >10 years 
and had significantly deranged glycemic indices. Periodic limb movements during sleep (PLMS) as reported by the bed 
partner or close family member were reported by 32(26.7%) of the diabetic subjects only; of which 21(65.6%) subjects 
had RLS. Sleep disturbances were more frequent among patients with RLS as compared to non-RLS (61.2% versus 
21.5%). According to Semmes-Weinstein filament test, 61% of diabetics and 67% of diabetic/RLS subjects had peripheral 
neuropathy. Interestingly, none of our subjects who were diagnosed as RLS was ever asked by their physician for symptoms 
of RLS prior to this study. Conclusion: RLS is a common problem among patients with type 2 diabetes mellitus and is 
associated with increasing age, peripheral neuropathy and impaired day time functioning. Poor recognition by physicians 
result in delayed diagnosis.
Keywords: Restless leg syndrome (RLS), diabetes mellitus, polyneuropathy
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INTRODUCTION
Restless legs syndrome (RLS) is a chronic sensorimotor 
disorder [1-4]. RLS can either be primary or secondary. 
Primary or idiopathic RLS, diagnosed when clinical 
conditions responsible for secondary forms are 
excluded by laboratory and clinical examinations, 
accounts for about 70 -80% of all RLS cases [1,5]. 
Among secondary or symptomatic forms, several conditions 
such as iron deficiency anemia, uremia, pregnancy, 
polyneuropathy and type 2 diabetes mellitus have been 
implicated in association with RLS [6-11]. RLS has 
recently been characterized by The International Restless 
Legs Syndrome Study Group (IRLSSG) as a clinical 
syndrome presenting as a combination of intense desire 
to move the limbs associated with paresthesias/dysesthesias; 
motor restlessness; exacerbation of symptoms with 
inactivity and relief by activity; and a nocturnal worsening 
in the symptom [12]. According to the Western data, it 
affects approximately 7-11.5% of the adult population 
and is found to be higher in women than in men. The 
intensity of sensory and motor symptoms generally 
tends to increase with advancing age. Alcoholics, smokers 
and selective serotonin reuptake inhibitor (SSRI) users 
as well as patients suffering from neuropathy are more 
likely to have RLS [2, 13-16]. Diabetes mellitus is a lifelong 
disease and a common cause of sensorimotor polyneu-
ropathy [13]. However, previous studies on RLS in 
diabetic neuropathy yielded conflicting results with a 
prevalence rate ranging from 8.8 to 27%, not significantly 
different even from controls in some studies [11, 17-18]. 
Poor glycemic control with RLS may also impact the 
associated consequences of diabetes mellitus including 
sleep quality, sleep cycle alterations, fatigue, and 
depression [19]. Norma G et al reported that diabetic 
people at risk for RLS were at increased risk for obstructive 
sleep apnea and insomnia-sleep problems often 
reported in diabetes [19]. Montplasir et al reported 
significant association between RLS and Periodic Limb 
Movements during Sleep (PLMS) during sleep or while 
INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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awake [20]. However, there is paucity of local data in this 
regard. We hypothesized that patients with type 2 
diabetes mellitus will show a high frequency of RLS.  
Therefore, we sought to determine the frequency of RLS 
in subjects with type 2 diabetes mellitus and its associ-
ated factors especially sleep disturbances, daytime 
time functioning  and PLMS. with non-adherence to 
AEDs and help in taking possible measures to improve 
antiepileptic drug compliance and prevent conse-
quences of uncontrolled seizures. The prevalence of 
epilepsy in Pakistan is about 9.99/1000.
METHODS
Patient selection
For this study, 120 consecutive subjects with type 2 
diabetes mellitus who attended the diabetes clinic of 
Jinnah Medical Dental College Hospital, Karachi from 
July 2009 to July 2010 were recruited. Ethical approval 
for the study was taken from local ethics review 
committee of the hospital. The non-diabetic group 
consisted of 54 consecutive patients who attended the 
medical outpatient clinics for some seasonal illness 
during the study period with no sign/symptom of any 
chronic disease. We included all the subjects who were 
30 years old or above, irrespective of the gender. We 
excluded all the patients who were known to have (or 
were being treated for) anemia, chronic liver disease, 
thyroid dysfunction, uremia and non-diabetic polyneu-
ropathy. Similarly, pregnant women were excluded from 
the study as RLS is already expected to be more prevalent 
in this set of population. Patients who had a language 
barrier were also excluded to minimize the biases in 
clinical findings and ensure the authenticity of information. 
All the participants provided an informed consent.
General Protocol
Records were reviewed and patients were interviewed 
using a closed ended questionnaire regarding their 
demographic aspects, past medical history, family 
history and use of medications. In particular, we 
inquired about the clinical conditions which support 
RLS (such as iron-deficiency anemia, hypothyroidism, 
uremia, and rheumatoid arthritis) and about the drugs 
which could possibly worsen RLS symptoms 
(antidepressants or antipsychotics) or rather improve 
RLS symptoms (dopaminergic agents, benzodiazepines, 
and anticonvulsants such as gabapentin, carbamazepine, 
oxcarbazepine, and valproic acid). Moreover, both 
diabetic and non-diabetic subjects were specifically 
asked for: (1) disturbance of sleep (2) daytime sleepiness 
(3) daytime dysfunction; and (4) presence of PLMS. Sleep 
disturbance was defined as difficulty in falling asleep 
and awakening. Daytime sleepiness was assessed by 
Epworth Sleepiness Scale (ESS) which is a validated 
tool. A score of >10 was indicative of excessive 
daytime sleepiness. [13] Patients were considered to 
have daytime dysfunctioning when they have a subjective 
complain about it. Presence of PLMS as reported by the 
bed partner or close family member was ascertained as 
described in the literature i.e. periodic jerky movements 
causing flexion of the ankle, knee, or hip; occasionally 
accompanied by arousals from sleep, leading to sleep 
fragmentation and excessive daytime sleepiness [18]. 
RLS Protocol
In all the study subjects, a neurologist confirmed the 
presence of RLS using the criteria defined by the Inter-
national Restless Legs Syndrome Study Group (IRLSSG) 
[12]. Only the patients who fulfilled all 4 criteria were 
considered affected by RLS and were further asked 
about the frequency, duration and intensity of the 
symptoms. Presence of RLS symptoms in first-degree 
relatives was established in both diabetic and non-
diabetic subjects.
 
Laboratory Data
Laboratory data was obtained at the time of interview 
for complete blood count, creatinine, random and 
fasting blood glucose in all subjects and for serum 
ferritin and glycosylated hemoglobin (HbA1c) in 79 and 
152 subjects respectively.
Evaluation of polyneuropathy
Distal sensory function was examined bilaterally using 
Semmes-Weinstein (SW) filaments as recommended by 
the World Health Organization and International Diabetes 
Federation for screening peripheral neuropathy in 
diabetic subjects [21]. The dorsal surface of the foot and 
the heel was tested in a random manner on 10 prede-
termined sites [21-22] with the filament pressed perpen-
dicularly, for 1 second, and pressure enough to bend 
the filament. Patient’s response was noted on the basis 
of yes/no option. Those patients who were able to 
perceive at less than 6 points were considered to have 
neuropathy [21].
Statistical Analysis
Sample size estimation: A sample size of at least 175 
was required to estimate the proportion of RLS among 
diabetics, however there is no literature available in our 
region assuming 10-15% prevalence in the regional 
population along with 80 percent power, 0.05 significance 
level, 5 percent bond on error, and 5% adjustment for 
non-response rate. As previously reported by Rozina S 
et al, RLS was seen in around 10% of the general 
population.[7] Data was entered and analyzed using 
Statistical Package Social Sciences (SPSS) version 
19.0. Initially descriptive statistics and frequencies and 
proportions were generated. Continuous variables were 
analyzed by t– test and categorical by chi-square or 
Fisher exact, where appropriate.  Later stepwise multi-
variable logistic regression was done to identify factors 
related with RLS among diabetics.
RESULTS
General characteristics of the diabetic and non-diabetic 
subjects are presented in Table 1. Diabetic subjects 
were comparably elder as compared to the non-diabetic 
subjects. Also, there was a slight preponderance of 
male gender in the diabetic subjects. Presence of sleep 
disorders, PLMS and RLS, family history of diabetes 
mellitus and RLS, and higher glycemic indices were 
significantly frequent among diabetic subjects. Only 
34% of the diabetic subjects had a value of HbA1c < 
7%. Most of the patients (94%) were taking oral hypo-
glycemic agents, the rest were on insulin therapy. PLMS 
were reported by 32 (26.7%) diabetics’ subjects only; 
of whom 21(65%) subjects had RLS. Sixty seven of the 
120 subjects with type 2 diabetes mellitus (55.8%) 
were diagnosed as having RLS (p < 0.05). Among 
these subjects, 28/67 (41.8%) had diabetes for < 
5years, 26/67 (38.8%) for >10 years, while the rest of 
them (13/67; 19.4%) had diabetes for 5-10 years. The 
laboratory parameters of RLS subjects revealed higher 
values for the glycemic indices including random and 
fasting blood sugar; and HbA1c level (Table 2). Among 
RLS subjects, none reported a positive family history of 
any sleep disorder which was in contrast to 4 (3.7%) of 
the non-RLS subjects. Among the subjects who did not 
fulfill the RLS criteria (n;53) the individual RLS like 
complains were evaluated. Unpleasant sensation in the 
legs with urge to move them was reported in 42.8%, 
worsening during inactivity or rest in 25.6%, relieved by 
activity in 18.1% while nocturnal worsening was 
reported by 22.4% of non- RLS subjects. Among RLS 
subjects, the majority of the subjects were using over-
the-counter analgesics (59/67; 88%). In univariate 
analysis, female gender, increasing age, clinical 
evidence of neuropathy, disturbance of sleep, daytime 
sleepiness, and impaired daytime functioning appeared 
as predictors of presence of RLS (Table 3). However, 
only advancing age, impaired daytime functioning and 
clinical evidence of neuropathy appeared as the predictors 
of RLS in multivariate analysis (Table 4). The multivariable 
analysis showed that having impaired daytime functioning 
due to sleep disorder was 47 times more associated 
with RLS adjusting for other covariates (adjusted Odds 
Ratio (OR) 47; 95% CI 10.3-217). Likewise, odds of 
having RLS among those with an evidence of neuropathy 
were 15 times more than those without neuropathy 
(adjusted OR= 15, 95% CI = 3.8-58). Every one year 
increase in age showed a 20% increase in risk of having 
RLS after adjusting other variables (Adjusted OR= 1.2, 
95% CI = 1.1-1.3). Interestingly, despite the high 
prevalence reported from the subcontinent, none of the 
non-diabetic subject suffered from either RLS or PLMS. 
To our surprise, none of the subjects who were 
diagnosed as RLS was ever asked by their physician for 
symptoms or diagnosis of RLS prior to this study.
DISCUSSION
The reported prevalence of RLS in general population by 
Western countries ranges between 5-15% [23] whereas 
data from Asian countries has reported a lower prevalence 
(1.5% in Japan [24], 1% in Singapore [25], 3.19% in 
Turkey [26]). Recently, higher prevalence rate i.e. 9.71% 
[27] has been reported by a Turkish study but their study 
population included subjects aged 40 years and above. 
Population based studies have found higher prevalence 
rates of RLS among subjects with advanced age, 
increased body mass index, smoking and diabetes 
mellitus [28,29]. Such varied differences in ranges might 
be due to the reason that some have heterogeneity in 
study design, study population and sample size. With 
no local data in this regard from Pakistan, this is the 
first Pakistani study confirming significant association 
between RLS and type 2 diabetes mellitus. The 
frequency of RLS in our diabetic subjects (55.8%) is 
significantly higher than compared to the international 
literature. Merlino et al diagnosed the RLS on the basis 
of International RLS Study Group criteria and reported a 
prevalence of 17.7% in their study population of 
diabetic subjects [4]. Lopes et al reported a comparatively 
higher frequency of RLS in 27% of the diabetic subjects 
[18], which is still lower than the frequency we found in 
our cohort. Peripheral neuropathy has been postulated 
to be associated with the pathogenesis of RLS. Qu S 
and Jensen et al have hypothesized that RLS in diabetic 
subjects could be due to the concurrence of decreased 
inhibitory dopaminergic control on the dorsal horns of 
the spinal gray matter [30-31] with the excitatory nociceptive 
inputs due to the peripheral neuropathy [32]. Various 
clinical studies have reported a significant association 
between RLS and polyneuropathy [8,33,34]. However, 
Skomro et al reported an insignificant association 
between RLS and diabetic polyneuropathy (p-value: 
0.78) [11]. In our study, odds of having RLS among 
those with an evidence of neuropathy were 15 times 
more than those without neuropathy (adjusted OR= 
15, 95% CI = 3.8-58). Diabetic subjects who were 
affected by RLS described their symptoms as an urge to 
move their limbs while those who had clinical evidence 
of neuropathy described their symptoms as pain, 
electric, or burning (pricking) sensations. This is in 
accordance with previous results shown by Winkelmann 
et al and Merlino et al [4, 35] A part from neuropathy, iron 
deficiency anemia is a well known contributor towards 
symptomatic form of RLS.[10] Our iron studies have 
shown insignificant association between RLS/diabetic+ 
subjects and iron studies which was in accordance with 
results demonstrated by previous studies [4, 11] thus 
further  pointing towards a lack of association. However, 
more clinic-pathological studies are needed to further 
verify this hypothesis. Significant number of RLS 
patients in our study reported sleep disturbance with 
daytime sleepiness and impaired daytime functioning 
which was consistent with results from previous studies 
on diabetic subjects. We found sleep disturbance to be 
associated with polyneuropathy and RLS. Similar correlation 
has been demonstrated by previous other studies [11, 14, 
36-37]. Our study has shown a significant association 
between RLS and PLMS as the majority of the PLMS 
patients were suffering from RLS too. In addition to 
diabetes, studies have also reported a significant association 
of RLS with diseases such as hypertension which could 
be due to concomitant sleep disturbances in such 
patients [38-41]. Advancing age and polyneuropathy have 
been shown to be associated with an increased preva-
lence of RLS [18,28]. The multivariate analysis established 
this association in our subjects as well (Table 2). A large 
number of our non-RLS subjects were those who 
suffered from a combination of symptoms included in 
the IRLSSG diagnostic criteria but they however, failed 
to meet all 4 criteria to be defined as RLS. We assume 
that these patients might be a potential case of RLS 
and may be defined as possible or probable RLS later. 
We propose that this criterion might be revised to take 
into account these large number of potential RLS 
patients so that early diagnosis and thus early identification 
of risk factors and their treatment might help them to 
enjoy a better quality of life. Interestingly, none of the 
non-diabetic subject suffered from either RLS or PLMS. 
Most importantly, none of our RLS subjects were ever 
asked by their physician for symptoms or diagnosis of 
RLS prior to this study. This may be because of the poor 
awareness of RLS among physicians as well.
LIMITATIONS
Our study was a single centered study so results cannot 
be generalized over the whole population. Ideally the 
patients who are suspected to have neuropathy by SW 
monofilament testing should undergo a standard nerve 
conduction study –the gold standard for the confirmation 
of neuropathy. Also, PLMS needs to be diagnosed with 
standard polysomnography.
STRENGTHS
This will be the first study from Pakistan which has 
addressed the frequency of RLS and its association with 
diabetes mellitus. Therefore, the results of this study 
are important as they provide the insight into this 
important and potentially treatable medical disorder in 
the local perspective. In addition to results shown 
above, our study has also shown the utility of SW mono-
filament in screening for the presence of sensory 
neuropathy. This is important in view of World Health 
Organization (WHO) report which has stated that 32% 
of the Pakistani population lives below poverty line. 
Hence, nerve conduction study (NCS/EMG) is not an 
economically pliable tool for the diagnosis of sensory 
neuropathy in our general community. So, SW filament 
utility has again come up in our study as a useful tool.
CONCLUSION
RLS is a common problem among patients with type 2 
diabetes mellitus and is associated with increasing age, 
peripheral neuropathy and impaired day time functioning. 
Its diagnosis is often delayed because of poor recognition 
by the physicians. Early diagnosis may result in 
improved quality of life of these patients. Considering a 
substantial number of subjects with one or more symptoms 
suggestive of RLS in the non-RLS group, further studies 
with larger sample size are needed to establish the 
importance of individual symptoms to guide the investi-
gation and the therapy in this sub-set of patients.
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INTRODUCTION
Restless legs syndrome (RLS) is a chronic sensorimotor 
disorder [1-4]. RLS can either be primary or secondary. 
Primary or idiopathic RLS, diagnosed when clinical 
conditions responsible for secondary forms are 
excluded by laboratory and clinical examinations, 
accounts for about 70 -80% of all RLS cases [1,5]. 
Among secondary or symptomatic forms, several conditions 
such as iron deficiency anemia, uremia, pregnancy, 
polyneuropathy and type 2 diabetes mellitus have been 
implicated in association with RLS [6-11]. RLS has 
recently been characterized by The International Restless 
Legs Syndrome Study Group (IRLSSG) as a clinical 
syndrome presenting as a combination of intense desire 
to move the limbs associated with paresthesias/dysesthesias; 
motor restlessness; exacerbation of symptoms with 
inactivity and relief by activity; and a nocturnal worsening 
in the symptom [12]. According to the Western data, it 
affects approximately 7-11.5% of the adult population 
and is found to be higher in women than in men. The 
intensity of sensory and motor symptoms generally 
tends to increase with advancing age. Alcoholics, smokers 
and selective serotonin reuptake inhibitor (SSRI) users 
as well as patients suffering from neuropathy are more 
likely to have RLS [2, 13-16]. Diabetes mellitus is a lifelong 
disease and a common cause of sensorimotor polyneu-
ropathy [13]. However, previous studies on RLS in 
diabetic neuropathy yielded conflicting results with a 
prevalence rate ranging from 8.8 to 27%, not significantly 
different even from controls in some studies [11, 17-18]. 
Poor glycemic control with RLS may also impact the 
associated consequences of diabetes mellitus including 
sleep quality, sleep cycle alterations, fatigue, and 
depression [19]. Norma G et al reported that diabetic 
people at risk for RLS were at increased risk for obstructive 
sleep apnea and insomnia-sleep problems often 
reported in diabetes [19]. Montplasir et al reported 
significant association between RLS and Periodic Limb 
Movements during Sleep (PLMS) during sleep or while 
INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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awake [20]. However, there is paucity of local data in this 
regard. We hypothesized that patients with type 2 
diabetes mellitus will show a high frequency of RLS.  
Therefore, we sought to determine the frequency of RLS 
in subjects with type 2 diabetes mellitus and its associ-
ated factors especially sleep disturbances, daytime 
time functioning  and PLMS. with non-adherence to 
AEDs and help in taking possible measures to improve 
antiepileptic drug compliance and prevent conse-
quences of uncontrolled seizures. The prevalence of 
epilepsy in Pakistan is about 9.99/1000.
METHODS
Patient selection
For this study, 120 consecutive subjects with type 2 
diabetes mellitus who attended the diabetes clinic of 
Jinnah Medical Dental College Hospital, Karachi from 
July 2009 to July 2010 were recruited. Ethical approval 
for the study was taken from local ethics review 
committee of the hospital. The non-diabetic group 
consisted of 54 consecutive patients who attended the 
medical outpatient clinics for some seasonal illness 
during the study period with no sign/symptom of any 
chronic disease. We included all the subjects who were 
30 years old or above, irrespective of the gender. We 
excluded all the patients who were known to have (or 
were being treated for) anemia, chronic liver disease, 
thyroid dysfunction, uremia and non-diabetic polyneu-
ropathy. Similarly, pregnant women were excluded from 
the study as RLS is already expected to be more prevalent 
in this set of population. Patients who had a language 
barrier were also excluded to minimize the biases in 
clinical findings and ensure the authenticity of information. 
All the participants provided an informed consent.
General Protocol
Records were reviewed and patients were interviewed 
using a closed ended questionnaire regarding their 
demographic aspects, past medical history, family 
history and use of medications. In particular, we 
inquired about the clinical conditions which support 
RLS (such as iron-deficiency anemia, hypothyroidism, 
uremia, and rheumatoid arthritis) and about the drugs 
which could possibly worsen RLS symptoms 
(antidepressants or antipsychotics) or rather improve 
RLS symptoms (dopaminergic agents, benzodiazepines, 
and anticonvulsants such as gabapentin, carbamazepine, 
oxcarbazepine, and valproic acid). Moreover, both 
diabetic and non-diabetic subjects were specifically 
asked for: (1) disturbance of sleep (2) daytime sleepiness 
(3) daytime dysfunction; and (4) presence of PLMS. Sleep 
disturbance was defined as difficulty in falling asleep 
and awakening. Daytime sleepiness was assessed by 
Epworth Sleepiness Scale (ESS) which is a validated 
tool. A score of >10 was indicative of excessive 
daytime sleepiness. [13] Patients were considered to 
have daytime dysfunctioning when they have a subjective 
complain about it. Presence of PLMS as reported by the 
bed partner or close family member was ascertained as 
described in the literature i.e. periodic jerky movements 
causing flexion of the ankle, knee, or hip; occasionally 
accompanied by arousals from sleep, leading to sleep 
fragmentation and excessive daytime sleepiness [18]. 
RLS Protocol
In all the study subjects, a neurologist confirmed the 
presence of RLS using the criteria defined by the Inter-
national Restless Legs Syndrome Study Group (IRLSSG) 
[12]. Only the patients who fulfilled all 4 criteria were 
considered affected by RLS and were further asked 
about the frequency, duration and intensity of the 
symptoms. Presence of RLS symptoms in first-degree 
relatives was established in both diabetic and non-
diabetic subjects.
 
Laboratory Data
Laboratory data was obtained at the time of interview 
for complete blood count, creatinine, random and 
fasting blood glucose in all subjects and for serum 
ferritin and glycosylated hemoglobin (HbA1c) in 79 and 
152 subjects respectively.
Evaluation of polyneuropathy
Distal sensory function was examined bilaterally using 
Semmes-Weinstein (SW) filaments as recommended by 
the World Health Organization and International Diabetes 
Federation for screening peripheral neuropathy in 
diabetic subjects [21]. The dorsal surface of the foot and 
the heel was tested in a random manner on 10 prede-
termined sites [21-22] with the filament pressed perpen-
dicularly, for 1 second, and pressure enough to bend 
the filament. Patient’s response was noted on the basis 
of yes/no option. Those patients who were able to 
perceive at less than 6 points were considered to have 
neuropathy [21].
Statistical Analysis
Sample size estimation: A sample size of at least 175 
was required to estimate the proportion of RLS among 
diabetics, however there is no literature available in our 
region assuming 10-15% prevalence in the regional 
population along with 80 percent power, 0.05 significance 
level, 5 percent bond on error, and 5% adjustment for 
non-response rate. As previously reported by Rozina S 
et al, RLS was seen in around 10% of the general 
population.[7] Data was entered and analyzed using 
Statistical Package Social Sciences (SPSS) version 
19.0. Initially descriptive statistics and frequencies and 
proportions were generated. Continuous variables were 
analyzed by t– test and categorical by chi-square or 
Fisher exact, where appropriate.  Later stepwise multi-
variable logistic regression was done to identify factors 
related with RLS among diabetics.
RESULTS
General characteristics of the diabetic and non-diabetic 
subjects are presented in Table 1. Diabetic subjects 
were comparably elder as compared to the non-diabetic 
subjects. Also, there was a slight preponderance of 
male gender in the diabetic subjects. Presence of sleep 
disorders, PLMS and RLS, family history of diabetes 
mellitus and RLS, and higher glycemic indices were 
significantly frequent among diabetic subjects. Only 
34% of the diabetic subjects had a value of HbA1c < 
7%. Most of the patients (94%) were taking oral hypo-
glycemic agents, the rest were on insulin therapy. PLMS 
were reported by 32 (26.7%) diabetics’ subjects only; 
of whom 21(65%) subjects had RLS. Sixty seven of the 
120 subjects with type 2 diabetes mellitus (55.8%) 
were diagnosed as having RLS (p < 0.05). Among 
these subjects, 28/67 (41.8%) had diabetes for < 
5years, 26/67 (38.8%) for >10 years, while the rest of 
them (13/67; 19.4%) had diabetes for 5-10 years. The 
laboratory parameters of RLS subjects revealed higher 
values for the glycemic indices including random and 
fasting blood sugar; and HbA1c level (Table 2). Among 
RLS subjects, none reported a positive family history of 
any sleep disorder which was in contrast to 4 (3.7%) of 
the non-RLS subjects. Among the subjects who did not 
fulfill the RLS criteria (n;53) the individual RLS like 
complains were evaluated. Unpleasant sensation in the 
legs with urge to move them was reported in 42.8%, 
worsening during inactivity or rest in 25.6%, relieved by 
activity in 18.1% while nocturnal worsening was 
reported by 22.4% of non- RLS subjects. Among RLS 
subjects, the majority of the subjects were using over-
the-counter analgesics (59/67; 88%). In univariate 
analysis, female gender, increasing age, clinical 
evidence of neuropathy, disturbance of sleep, daytime 
sleepiness, and impaired daytime functioning appeared 
as predictors of presence of RLS (Table 3). However, 
only advancing age, impaired daytime functioning and 
clinical evidence of neuropathy appeared as the predictors 
of RLS in multivariate analysis (Table 4). The multivariable 
analysis showed that having impaired daytime functioning 
due to sleep disorder was 47 times more associated 
with RLS adjusting for other covariates (adjusted Odds 
Ratio (OR) 47; 95% CI 10.3-217). Likewise, odds of 
having RLS among those with an evidence of neuropathy 
were 15 times more than those without neuropathy 
(adjusted OR= 15, 95% CI = 3.8-58). Every one year 
increase in age showed a 20% increase in risk of having 
RLS after adjusting other variables (Adjusted OR= 1.2, 
95% CI = 1.1-1.3). Interestingly, despite the high 
prevalence reported from the subcontinent, none of the 
non-diabetic subject suffered from either RLS or PLMS. 
To our surprise, none of the subjects who were 
diagnosed as RLS was ever asked by their physician for 
symptoms or diagnosis of RLS prior to this study.
DISCUSSION
The reported prevalence of RLS in general population by 
Western countries ranges between 5-15% [23] whereas 
data from Asian countries has reported a lower prevalence 
(1.5% in Japan [24], 1% in Singapore [25], 3.19% in 
Turkey [26]). Recently, higher prevalence rate i.e. 9.71% 
[27] has been reported by a Turkish study but their study 
population included subjects aged 40 years and above. 
Population based studies have found higher prevalence 
rates of RLS among subjects with advanced age, 
increased body mass index, smoking and diabetes 
mellitus [28,29]. Such varied differences in ranges might 
be due to the reason that some have heterogeneity in 
study design, study population and sample size. With 
no local data in this regard from Pakistan, this is the 
first Pakistani study confirming significant association 
between RLS and type 2 diabetes mellitus. The 
frequency of RLS in our diabetic subjects (55.8%) is 
significantly higher than compared to the international 
literature. Merlino et al diagnosed the RLS on the basis 
of International RLS Study Group criteria and reported a 
prevalence of 17.7% in their study population of 
diabetic subjects [4]. Lopes et al reported a comparatively 
higher frequency of RLS in 27% of the diabetic subjects 
[18], which is still lower than the frequency we found in 
our cohort. Peripheral neuropathy has been postulated 
to be associated with the pathogenesis of RLS. Qu S 
and Jensen et al have hypothesized that RLS in diabetic 
subjects could be due to the concurrence of decreased 
inhibitory dopaminergic control on the dorsal horns of 
the spinal gray matter [30-31] with the excitatory nociceptive 
inputs due to the peripheral neuropathy [32]. Various 
clinical studies have reported a significant association 
between RLS and polyneuropathy [8,33,34]. However, 
Skomro et al reported an insignificant association 
between RLS and diabetic polyneuropathy (p-value: 
0.78) [11]. In our study, odds of having RLS among 
those with an evidence of neuropathy were 15 times 
more than those without neuropathy (adjusted OR= 
15, 95% CI = 3.8-58). Diabetic subjects who were 
affected by RLS described their symptoms as an urge to 
move their limbs while those who had clinical evidence 
of neuropathy described their symptoms as pain, 
electric, or burning (pricking) sensations. This is in 
accordance with previous results shown by Winkelmann 
et al and Merlino et al [4, 35] A part from neuropathy, iron 
deficiency anemia is a well known contributor towards 
symptomatic form of RLS.[10] Our iron studies have 
shown insignificant association between RLS/diabetic+ 
subjects and iron studies which was in accordance with 
results demonstrated by previous studies [4, 11] thus 
further  pointing towards a lack of association. However, 
more clinic-pathological studies are needed to further 
verify this hypothesis. Significant number of RLS 
patients in our study reported sleep disturbance with 
daytime sleepiness and impaired daytime functioning 
which was consistent with results from previous studies 
on diabetic subjects. We found sleep disturbance to be 
associated with polyneuropathy and RLS. Similar correlation 
has been demonstrated by previous other studies [11, 14, 
36-37]. Our study has shown a significant association 
between RLS and PLMS as the majority of the PLMS 
patients were suffering from RLS too. In addition to 
diabetes, studies have also reported a significant association 
of RLS with diseases such as hypertension which could 
be due to concomitant sleep disturbances in such 
patients [38-41]. Advancing age and polyneuropathy have 
been shown to be associated with an increased preva-
lence of RLS [18,28]. The multivariate analysis established 
this association in our subjects as well (Table 2). A large 
number of our non-RLS subjects were those who 
suffered from a combination of symptoms included in 
the IRLSSG diagnostic criteria but they however, failed 
to meet all 4 criteria to be defined as RLS. We assume 
that these patients might be a potential case of RLS 
and may be defined as possible or probable RLS later. 
We propose that this criterion might be revised to take 
into account these large number of potential RLS 
patients so that early diagnosis and thus early identification 
of risk factors and their treatment might help them to 
enjoy a better quality of life. Interestingly, none of the 
non-diabetic subject suffered from either RLS or PLMS. 
Most importantly, none of our RLS subjects were ever 
asked by their physician for symptoms or diagnosis of 
RLS prior to this study. This may be because of the poor 
awareness of RLS among physicians as well.
LIMITATIONS
Our study was a single centered study so results cannot 
be generalized over the whole population. Ideally the 
patients who are suspected to have neuropathy by SW 
monofilament testing should undergo a standard nerve 
conduction study –the gold standard for the confirmation 
of neuropathy. Also, PLMS needs to be diagnosed with 
standard polysomnography.
STRENGTHS
This will be the first study from Pakistan which has 
addressed the frequency of RLS and its association with 
diabetes mellitus. Therefore, the results of this study 
are important as they provide the insight into this 
important and potentially treatable medical disorder in 
the local perspective. In addition to results shown 
above, our study has also shown the utility of SW mono-
filament in screening for the presence of sensory 
neuropathy. This is important in view of World Health 
Organization (WHO) report which has stated that 32% 
of the Pakistani population lives below poverty line. 
Hence, nerve conduction study (NCS/EMG) is not an 
economically pliable tool for the diagnosis of sensory 
neuropathy in our general community. So, SW filament 
utility has again come up in our study as a useful tool.
CONCLUSION
RLS is a common problem among patients with type 2 
diabetes mellitus and is associated with increasing age, 
peripheral neuropathy and impaired day time functioning. 
Its diagnosis is often delayed because of poor recognition 
by the physicians. Early diagnosis may result in 
improved quality of life of these patients. Considering a 
substantial number of subjects with one or more symptoms 
suggestive of RLS in the non-RLS group, further studies 
with larger sample size are needed to establish the 
importance of individual symptoms to guide the investi-
gation and the therapy in this sub-set of patients.
REFERENCES
1.   Bosco D, Plastino M, Fava A, Ettore M, Bosco F,
     Ermio C, Tallarigo F, Pirritano D, Consoli D. Role of 
     the Oral Glucose Tolerance Test (OGTT) in the 
     idiopathic restless legs syndrome. J Neurol Sci. 
     2009;287(1-2):60-63.
2.   Garcia-Borreguero D, Egatz R, Winkelmann J, 
     Berger K. Epidemiology of restless legs syndrome: 
     the current status. Sleep Med Rev. 2006;10(3): 
     153-167.
3.   Pascale VS, Damien C, Karine D, Christine B, 
     Philippe B and Richard T. Is restless legs syndrome 
     under recognized? Current management. Joint 
     Bone Spine. 2006;73(4);369-373.
4.   Merlino G, Fratticci L, Valente M, Del Giudice A, 
     Noacco C, Dolso P, Cancelli I, Scalise A, Gigli GL. 
     Association of restless legs syndrome in type 2 
     diabetes: a case-control study. Sleep. 2007;30 
     (7):866-871.
5.   Merlino G, Valente M, Serafini A, Fratticci L, Del 
     Giudice A, Piani A, Noacco C, Gigli GL. Effects of 
      restless legs syndrome on quality of life and psychological 
     status in patients with type 2 diabetes. Diabetes 
     Educ. 2010;36(1):79-87.
6.   Manconi M, Govoni V, De Vito A, Economou NT, 
     Cesnik E, Casetta I, Mollica G, Ferini-Strambi L, 
     Granieri E. Restless legs syndrome and pregnancy. 
     Neurology. 2004;63(6):1065-1069.
7.   Sikandar R, Khealani BA, Wasay M. Predictors of 
     restless legs syndrome in pregnancy: a hospital 
     based cross sectional survey from Pakistan. Sleep 
     Med. 2009;10(6):676-678.
8.   Nineb A, Rosso C, Dumurgier J, Nordine T, Lefaucheur 
     JP, Cre´ange A. Restless legs syndrome is 
     frequently overlooked in patients being evaluated 
     for polyneuropathies. Eur J Neurol. 2007; 14(7) : 
     788–792.
9.   Gigli GL, Adorati M, Dolso P, Piani A, Valente M, 
     Brotini S, Budai R: Restless legs syndrome in 
      end-stage renal disease. Sleep Med. 2004; 5 (3) : 
     309-315.
10. O'Keeffe ST, Gavin K, Lavan JN: Iron status and 
     restless legs syndrome in the elderly. Age Ageing. 
     1994;23(3):200-203.
11. Skomro RP, Ludwig S, Salamon E, Kryger MH. 
     Sleep complaints and restless legs syndrome in 
     adult type 2 diabetics. Sleep Med. 2001;2(5) : 
     417-422.
12. Walters AS, LeBrocq C, Dhar A, Hening W, Rosen 
     R, Allen RP, Trenkwalder C. Validation of the Inter- 
     national Restless Legs Syndrome Study Group 
     rating scale for restless legs syndrome. Sleep Med. 
     2003;4 (2):121-132.
13. Lopes LA, Lins Cde M, Adeodato VG, Quental DP, 
     de Bruin PF, Montenegro RM, Jr., de Bruin VM. 
     Restless legs syndrome and quality of sleep in type 
     2 diabetes. Diabetes Care. 2005;28(11):2633-2636.
14. Cuellar NG, Ratcliffe SJ. Restless legs syndrome in 
     type 2 diabetes: implications to diabetes educators. 
     Diabetes Educ. 2008;34(2):218-234.
15. Ohayon MM, Roth T. Prevalence of restless leg 
     syndrome and periodic limb movement disorder in 
     the general population. J Psychosom Res. 2002; 
     53 (1) :547-554.
16. Gamaldo CE, Earley CJ. Restless legs syndrome: a 
     clinical update. Chest. 2006;130(5):1596-1604.
17. Gemignani F, Brindani F, Vitetta F, Marbini A, 
     Calzetti S. Restless legs syndrome in diabetic 
     neuropathy: a frequent manifestation of small fiber 
     neuropathy. J Peripher Nerv Syst. 2007;12 (1) : 
     50-53.
18. Cuellar NG, Ratcliffe SJ. A Comparison of Glycemic 
     Control, Sleep, Fatigue, and Depression in Type 2 
     Diabetes with and without Restless Legs 
     Syndrome. J Clin Sleep Med. 2008;4(1):50-56.
19. Montplaisir J, Boucher S, Poirier G, Lavigne G, 
     Lapierre O, Lesperance P. Clinical, polysomnographic, 
     and genetic characteristics of restless legs 
     syndrome: a study of 133 patients diagnosed with 
     new standard criteria. Mov Disord. 1997; 12(1) : 6 
     1-65.
20. Lee S, Kim H, Choi S, Park Y, Kim Y, Cho B. Clinical 
     Usefulness of the Two-site Semmes-Weinstein 
     Monofilament Test for Detecting Diabetic Peripheral 
     Neuropathy. J Korean Med Sci. 2003; 18(1) : 1 
     03-7.
21. Armstrong DG, Lavery LA, Vela SA, Quebedeaux TL, 
     Fleischli JG: Choosing a Practical Screening Instrument 
     to Identify Patients at Risk for Diabetic Foot Ulceration. 
     Arch Intern Med. 1998;158(3):289-292.
22. Zucconi M, Ferini-Strambi L: Epidemiology and 
     clinical findings of restless legs syndrome. Sleep 
     Med. 2004;5(3):293-299.
23. Kageyama T, Kabuto M, Nitta H, Kurokawa Y, Taira 
     K, Suzuki S, Takemoto T: Prevalence of periodic 
     limb movement-like and restless legs-like symptoms 
     among Japanese adults. Psychiatry Clin Neurosci. 
     2000;54(3):296–8. 
24. Tan EK, Seah A, See SJ, Lim E, Wong MC, Koh KK: 
     Restless legs syndrome in an Asian population: A 
     study in Singapore. Mov Disord. 2001;16 (3) : 5 7 
     7-579.
25. Sevim S, Dogu O, Camdeviren H, Bugdayci R, 
     Sasmaz T, Kaleagasi H, Aral M, Helvaci I: Unexpectedly 
     low prevalence and unusual characteristics of RLS 
     in Mersin, Turkey. Neurology. 2003;61(11):1562 
     1569.
26. Erer S, Karli N, Zarifoglu M, Ozcakir A, Yildiz D: The 
     prevalence and clinical features of restless legs 
     syndrome: a door to door population study in 
     Orhangazi, Bursa in Turkey. Neurol India. 
     2009;57(6):729-733.
27. Phillips B, Young T, Finn L, Asher K, Hening WA, 
     Purvis C: Epidemiology of restless legs symptoms 
     in adults. Arch Intern Med. 2000;160(14):2137-2 
     141.
28. Berger K, Luedemann J, Trenkwalder C, John U, 
     Kessler C: Sex and the risk of restless legs 
     syndrome in the general population. Arch Intern 
     Med. 2004;164(2):196-202.
29. Qu S, Ondo WG, Zhang X, Xie WJ, Pan TH, Le WD: 
     Projections of diencephalic dopamine neurones 
     into the spina l cord in mice. Exp Brain Res. 2006; 
     168(1-2):152-6.
30. Jensen TS, Smith DF: Dopaminergic effects on 
     tail-flick response in spinal rats. Eur J Pharmacol. 
     1982;79(1-2):129-133.
31. Handwerker HO, Iggo A, Zimmermann M: Segmental 
     and supraspinal actions on dorsal horn neurons 
     responding to noxious and non-noxious skin 
     stimuli. Pain. 1975;1(2):147-165.
32. Gemignani F, Brindani F, Negrotti A, Vitetta F, Alfieri 
     S, Marbini A. Restless legs syndrome and polyneu- 
     ropathy. Mov Disord. 2006;21(8):1254-1257.
33. Polydefkis M, Allen RP, Hauer P, Earley CJ, Griffin 
     JW and Mc-Arthur JC. Subclinical sensory polyneu- 
     ropathy in late onset restless legs syndrome. 
     Neurology. 2000;55(8):1115-1121.
34. Winkelmann J, Wetter TC, Collado-Seidel V, Gasser 
     T, Dichgans M, Yassouridis A, Trenkwalder C. 
     Clinical characteristics and frequency of the 
     hereditary restless legs syndrome in a population 
     of 300 patients. Sleep. 2000;23(5):597-602.
35. Kawakami N, Takatsuka N, Shimizu H. Sleep 
     disturbance and onset of type 2 diabetes. Diabetes 
     Care. 2004;27(1):282-283.
36. Resnick HE, Redline S, Shahar E, Gilpin A, 
     Newman A, Walter R, Ewy GA, Howard BV, Punjabi 
     NM. Diabetes and sleep disturbances: findings 
     from the Sleep Heart Health Study. Diabetes Care. 
     2003;26(3):702-709.
37. Gangwisch JE, Heymsfield SB, Boden-Albala B et 
     al Gangwisch JE, Heymsfield SB, Boden-Albala B, 
     Buijs RM, Kreier F, Pickering TG, Rundle AG, 
     Zammit GK, Malaspina D. Short sleep duration as 
     a risk factor for hypertension: analyses of the first 
     National Health and Nutrition Examination Survey. 
     Hypertension. 2006;47(5):833-839.
38. Gottlieb DJ, Redline S, Nieto FJ, Baldwin CM, 
     Newman AB, Resnick HE, Punjabi NM. Association 
     of usual sleep duration with hypertension: the 
     Sleep Heart Health Study. Sleep. 2006 ; 29 (8) : 
     1009-1 014.
39. Spiegel K, Knutson K, Leproult R, Tasali E, Van 
     Cauter E: Sleep loss: a novel risk factor for insulin 
     resistance and Type 2 diabetes. J Appl Physiol. 
     2005;99(5):2008-2019.
40. Nilsson PM, Roost M, Engstrom G, Hedblad B, 
     Berglund G. Incidence of diabetes in middle-aged 
     men is related to sleep disturbances. Diabetes 
     Care. 2004;27(10):2464-2469.
1 6 V O L .  1 0  ( 1 )  J A N   -   M A R C H   2 0 1 5P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S
INTRODUCTION
Restless legs syndrome (RLS) is a chronic sensorimotor 
disorder [1-4]. RLS can either be primary or secondary. 
Primary or idiopathic RLS, diagnosed when clinical 
conditions responsible for secondary forms are 
excluded by laboratory and clinical examinations, 
accounts for about 70 -80% of all RLS cases [1,5]. 
Among secondary or symptomatic forms, several conditions 
such as iron deficiency anemia, uremia, pregnancy, 
polyneuropathy and type 2 diabetes mellitus have been 
implicated in association with RLS [6-11]. RLS has 
recently been characterized by The International Restless 
Legs Syndrome Study Group (IRLSSG) as a clinical 
syndrome presenting as a combination of intense desire 
to move the limbs associated with paresthesias/dysesthesias; 
motor restlessness; exacerbation of symptoms with 
inactivity and relief by activity; and a nocturnal worsening 
in the symptom [12]. According to the Western data, it 
affects approximately 7-11.5% of the adult population 
and is found to be higher in women than in men. The 
intensity of sensory and motor symptoms generally 
tends to increase with advancing age. Alcoholics, smokers 
and selective serotonin reuptake inhibitor (SSRI) users 
as well as patients suffering from neuropathy are more 
likely to have RLS [2, 13-16]. Diabetes mellitus is a lifelong 
disease and a common cause of sensorimotor polyneu-
ropathy [13]. However, previous studies on RLS in 
diabetic neuropathy yielded conflicting results with a 
prevalence rate ranging from 8.8 to 27%, not significantly 
different even from controls in some studies [11, 17-18]. 
Poor glycemic control with RLS may also impact the 
associated consequences of diabetes mellitus including 
sleep quality, sleep cycle alterations, fatigue, and 
depression [19]. Norma G et al reported that diabetic 
people at risk for RLS were at increased risk for obstructive 
sleep apnea and insomnia-sleep problems often 
reported in diabetes [19]. Montplasir et al reported 
significant association between RLS and Periodic Limb 
Movements during Sleep (PLMS) during sleep or while 
INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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awake [20]. However, there is paucity of local data in this 
regard. We hypothesized that patients with type 2 
diabetes mellitus will show a high frequency of RLS.  
Therefore, we sought to determine the frequency of RLS 
in subjects with type 2 diabetes mellitus and its associ-
ated factors especially sleep disturbances, daytime 
time functioning  and PLMS. with non-adherence to 
AEDs and help in taking possible measures to improve 
antiepileptic drug compliance and prevent conse-
quences of uncontrolled seizures. The prevalence of 
epilepsy in Pakistan is about 9.99/1000.
METHODS
Patient selection
For this study, 120 consecutive subjects with type 2 
diabetes mellitus who attended the diabetes clinic of 
Jinnah Medical Dental College Hospital, Karachi from 
July 2009 to July 2010 were recruited. Ethical approval 
for the study was taken from local ethics review 
committee of the hospital. The non-diabetic group 
consisted of 54 consecutive patients who attended the 
medical outpatient clinics for some seasonal illness 
during the study period with no sign/symptom of any 
chronic disease. We included all the subjects who were 
30 years old or above, irrespective of the gender. We 
excluded all the patients who were known to have (or 
were being treated for) anemia, chronic liver disease, 
thyroid dysfunction, uremia and non-diabetic polyneu-
ropathy. Similarly, pregnant women were excluded from 
the study as RLS is already expected to be more prevalent 
in this set of population. Patients who had a language 
barrier were also excluded to minimize the biases in 
clinical findings and ensure the authenticity of information. 
All the participants provided an informed consent.
General Protocol
Records were reviewed and patients were interviewed 
using a closed ended questionnaire regarding their 
demographic aspects, past medical history, family 
history and use of medications. In particular, we 
inquired about the clinical conditions which support 
RLS (such as iron-deficiency anemia, hypothyroidism, 
uremia, and rheumatoid arthritis) and about the drugs 
which could possibly worsen RLS symptoms 
(antidepressants or antipsychotics) or rather improve 
RLS symptoms (dopaminergic agents, benzodiazepines, 
and anticonvulsants such as gabapentin, carbamazepine, 
oxcarbazepine, and valproic acid). Moreover, both 
diabetic and non-diabetic subjects were specifically 
asked for: (1) disturbance of sleep (2) daytime sleepiness 
(3) daytime dysfunction; and (4) presence of PLMS. Sleep 
disturbance was defined as difficulty in falling asleep 
and awakening. Daytime sleepiness was assessed by 
Epworth Sleepiness Scale (ESS) which is a validated 
tool. A score of >10 was indicative of excessive 
daytime sleepiness. [13] Patients were considered to 
have daytime dysfunctioning when they have a subjective 
complain about it. Presence of PLMS as reported by the 
bed partner or close family member was ascertained as 
described in the literature i.e. periodic jerky movements 
causing flexion of the ankle, knee, or hip; occasionally 
accompanied by arousals from sleep, leading to sleep 
fragmentation and excessive daytime sleepiness [18]. 
RLS Protocol
In all the study subjects, a neurologist confirmed the 
presence of RLS using the criteria defined by the Inter-
national Restless Legs Syndrome Study Group (IRLSSG) 
[12]. Only the patients who fulfilled all 4 criteria were 
considered affected by RLS and were further asked 
about the frequency, duration and intensity of the 
symptoms. Presence of RLS symptoms in first-degree 
relatives was established in both diabetic and non-
diabetic subjects.
 
Laboratory Data
Laboratory data was obtained at the time of interview 
for complete blood count, creatinine, random and 
fasting blood glucose in all subjects and for serum 
ferritin and glycosylated hemoglobin (HbA1c) in 79 and 
152 subjects respectively.
Evaluation of polyneuropathy
Distal sensory function was examined bilaterally using 
Semmes-Weinstein (SW) filaments as recommended by 
the World Health Organization and International Diabetes 
Federation for screening peripheral neuropathy in 
diabetic subjects [21]. The dorsal surface of the foot and 
the heel was tested in a random manner on 10 prede-
termined sites [21-22] with the filament pressed perpen-
dicularly, for 1 second, and pressure enough to bend 
the filament. Patient’s response was noted on the basis 
of yes/no option. Those patients who were able to 
perceive at less than 6 points were considered to have 
neuropathy [21].
Statistical Analysis
Sample size estimation: A sample size of at least 175 
was required to estimate the proportion of RLS among 
diabetics, however there is no literature available in our 
region assuming 10-15% prevalence in the regional 
population along with 80 percent power, 0.05 significance 
level, 5 percent bond on error, and 5% adjustment for 
non-response rate. As previously reported by Rozina S 
et al, RLS was seen in around 10% of the general 
population.[7] Data was entered and analyzed using 
Statistical Package Social Sciences (SPSS) version 
19.0. Initially descriptive statistics and frequencies and 
proportions were generated. Continuous variables were 
analyzed by t– test and categorical by chi-square or 
Fisher exact, where appropriate.  Later stepwise multi-
variable logistic regression was done to identify factors 
related with RLS among diabetics.
RESULTS
General characteristics of the diabetic and non-diabetic 
subjects are presented in Table 1. Diabetic subjects 
were comparably elder as compared to the non-diabetic 
subjects. Also, there was a slight preponderance of 
male gender in the diabetic subjects. Presence of sleep 
disorders, PLMS and RLS, family history of diabetes 
mellitus and RLS, and higher glycemic indices were 
significantly frequent among diabetic subjects. Only 
34% of the diabetic subjects had a value of HbA1c < 
7%. Most of the patients (94%) were taking oral hypo-
glycemic agents, the rest were on insulin therapy. PLMS 
were reported by 32 (26.7%) diabetics’ subjects only; 
of whom 21(65%) subjects had RLS. Sixty seven of the 
120 subjects with type 2 diabetes mellitus (55.8%) 
were diagnosed as having RLS (p < 0.05). Among 
these subjects, 28/67 (41.8%) had diabetes for < 
5years, 26/67 (38.8%) for >10 years, while the rest of 
them (13/67; 19.4%) had diabetes for 5-10 years. The 
laboratory parameters of RLS subjects revealed higher 
values for the glycemic indices including random and 
fasting blood sugar; and HbA1c level (Table 2). Among 
RLS subjects, none reported a positive family history of 
any sleep disorder which was in contrast to 4 (3.7%) of 
the non-RLS subjects. Among the subjects who did not 
fulfill the RLS criteria (n;53) the individual RLS like 
complains were evaluated. Unpleasant sensation in the 
legs with urge to move them was reported in 42.8%, 
worsening during inactivity or rest in 25.6%, relieved by 
activity in 18.1% while nocturnal worsening was 
reported by 22.4% of non- RLS subjects. Among RLS 
subjects, the majority of the subjects were using over-
the-counter analgesics (59/67; 88%). In univariate 
analysis, female gender, increasing age, clinical 
evidence of neuropathy, disturbance of sleep, daytime 
sleepiness, and impaired daytime functioning appeared 
as predictors of presence of RLS (Table 3). However, 
only advancing age, impaired daytime functioning and 
clinical evidence of neuropathy appeared as the predictors 
of RLS in multivariate analysis (Table 4). The multivariable 
analysis showed that having impaired daytime functioning 
due to sleep disorder was 47 times more associated 
with RLS adjusting for other covariates (adjusted Odds 
Ratio (OR) 47; 95% CI 10.3-217). Likewise, odds of 
having RLS among those with an evidence of neuropathy 
were 15 times more than those without neuropathy 
(adjusted OR= 15, 95% CI = 3.8-58). Every one year 
increase in age showed a 20% increase in risk of having 
RLS after adjusting other variables (Adjusted OR= 1.2, 
95% CI = 1.1-1.3). Interestingly, despite the high 
prevalence reported from the subcontinent, none of the 
non-diabetic subject suffered from either RLS or PLMS. 
To our surprise, none of the subjects who were 
diagnosed as RLS was ever asked by their physician for 
symptoms or diagnosis of RLS prior to this study.
DISCUSSION
The reported prevalence of RLS in general population by 
Western countries ranges between 5-15% [23] whereas 
data from Asian countries has reported a lower prevalence 
(1.5% in Japan [24], 1% in Singapore [25], 3.19% in 
Turkey [26]). Recently, higher prevalence rate i.e. 9.71% 
[27] has been reported by a Turkish study but their study 
population included subjects aged 40 years and above. 
Population based studies have found higher prevalence 
rates of RLS among subjects with advanced age, 
increased body mass index, smoking and diabetes 
mellitus [28,29]. Such varied differences in ranges might 
be due to the reason that some have heterogeneity in 
study design, study population and sample size. With 
no local data in this regard from Pakistan, this is the 
first Pakistani study confirming significant association 
between RLS and type 2 diabetes mellitus. The 
frequency of RLS in our diabetic subjects (55.8%) is 
significantly higher than compared to the international 
literature. Merlino et al diagnosed the RLS on the basis 
of International RLS Study Group criteria and reported a 
prevalence of 17.7% in their study population of 
diabetic subjects [4]. Lopes et al reported a comparatively 
higher frequency of RLS in 27% of the diabetic subjects 
[18], which is still lower than the frequency we found in 
our cohort. Peripheral neuropathy has been postulated 
to be associated with the pathogenesis of RLS. Qu S 
and Jensen et al have hypothesized that RLS in diabetic 
subjects could be due to the concurrence of decreased 
inhibitory dopaminergic control on the dorsal horns of 
the spinal gray matter [30-31] with the excitatory nociceptive 
inputs due to the peripheral neuropathy [32]. Various 
clinical studies have reported a significant association 
between RLS and polyneuropathy [8,33,34]. However, 
Skomro et al reported an insignificant association 
between RLS and diabetic polyneuropathy (p-value: 
0.78) [11]. In our study, odds of having RLS among 
those with an evidence of neuropathy were 15 times 
more than those without neuropathy (adjusted OR= 
15, 95% CI = 3.8-58). Diabetic subjects who were 
affected by RLS described their symptoms as an urge to 
move their limbs while those who had clinical evidence 
of neuropathy described their symptoms as pain, 
electric, or burning (pricking) sensations. This is in 
accordance with previous results shown by Winkelmann 
et al and Merlino et al [4, 35] A part from neuropathy, iron 
deficiency anemia is a well known contributor towards 
symptomatic form of RLS.[10] Our iron studies have 
shown insignificant association between RLS/diabetic+ 
subjects and iron studies which was in accordance with 
results demonstrated by previous studies [4, 11] thus 
further  pointing towards a lack of association. However, 
more clinic-pathological studies are needed to further 
verify this hypothesis. Significant number of RLS 
patients in our study reported sleep disturbance with 
daytime sleepiness and impaired daytime functioning 
which was consistent with results from previous studies 
on diabetic subjects. We found sleep disturbance to be 
associated with polyneuropathy and RLS. Similar correlation 
has been demonstrated by previous other studies [11, 14, 
36-37]. Our study has shown a significant association 
between RLS and PLMS as the majority of the PLMS 
patients were suffering from RLS too. In addition to 
diabetes, studies have also reported a significant association 
of RLS with diseases such as hypertension which could 
be due to concomitant sleep disturbances in such 
patients [38-41]. Advancing age and polyneuropathy have 
been shown to be associated with an increased preva-
lence of RLS [18,28]. The multivariate analysis established 
this association in our subjects as well (Table 2). A large 
number of our non-RLS subjects were those who 
suffered from a combination of symptoms included in 
the IRLSSG diagnostic criteria but they however, failed 
to meet all 4 criteria to be defined as RLS. We assume 
that these patients might be a potential case of RLS 
and may be defined as possible or probable RLS later. 
We propose that this criterion might be revised to take 
into account these large number of potential RLS 
patients so that early diagnosis and thus early identification 
of risk factors and their treatment might help them to 
enjoy a better quality of life. Interestingly, none of the 
non-diabetic subject suffered from either RLS or PLMS. 
Most importantly, none of our RLS subjects were ever 
asked by their physician for symptoms or diagnosis of 
RLS prior to this study. This may be because of the poor 
awareness of RLS among physicians as well.
LIMITATIONS
Our study was a single centered study so results cannot 
be generalized over the whole population. Ideally the 
patients who are suspected to have neuropathy by SW 
monofilament testing should undergo a standard nerve 
conduction study –the gold standard for the confirmation 
of neuropathy. Also, PLMS needs to be diagnosed with 
standard polysomnography.
STRENGTHS
This will be the first study from Pakistan which has 
addressed the frequency of RLS and its association with 
diabetes mellitus. Therefore, the results of this study 
are important as they provide the insight into this 
important and potentially treatable medical disorder in 
the local perspective. In addition to results shown 
above, our study has also shown the utility of SW mono-
filament in screening for the presence of sensory 
neuropathy. This is important in view of World Health 
Organization (WHO) report which has stated that 32% 
of the Pakistani population lives below poverty line. 
Hence, nerve conduction study (NCS/EMG) is not an 
economically pliable tool for the diagnosis of sensory 
neuropathy in our general community. So, SW filament 
utility has again come up in our study as a useful tool.
CONCLUSION
RLS is a common problem among patients with type 2 
diabetes mellitus and is associated with increasing age, 
peripheral neuropathy and impaired day time functioning. 
Its diagnosis is often delayed because of poor recognition 
by the physicians. Early diagnosis may result in 
improved quality of life of these patients. Considering a 
substantial number of subjects with one or more symptoms 
suggestive of RLS in the non-RLS group, further studies 
with larger sample size are needed to establish the 
importance of individual symptoms to guide the investi-
gation and the therapy in this sub-set of patients.
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INTRODUCTION
Restless legs syndrome (RLS) is a chronic sensorimotor 
disorder [1-4]. RLS can either be primary or secondary. 
Primary or idiopathic RLS, diagnosed when clinical 
conditions responsible for secondary forms are 
excluded by laboratory and clinical examinations, 
accounts for about 70 -80% of all RLS cases [1,5]. 
Among secondary or symptomatic forms, several conditions 
such as iron deficiency anemia, uremia, pregnancy, 
polyneuropathy and type 2 diabetes mellitus have been 
implicated in association with RLS [6-11]. RLS has 
recently been characterized by The International Restless 
Legs Syndrome Study Group (IRLSSG) as a clinical 
syndrome presenting as a combination of intense desire 
to move the limbs associated with paresthesias/dysesthesias; 
motor restlessness; exacerbation of symptoms with 
inactivity and relief by activity; and a nocturnal worsening 
in the symptom [12]. According to the Western data, it 
affects approximately 7-11.5% of the adult population 
and is found to be higher in women than in men. The 
intensity of sensory and motor symptoms generally 
tends to increase with advancing age. Alcoholics, smokers 
and selective serotonin reuptake inhibitor (SSRI) users 
as well as patients suffering from neuropathy are more 
likely to have RLS [2, 13-16]. Diabetes mellitus is a lifelong 
disease and a common cause of sensorimotor polyneu-
ropathy [13]. However, previous studies on RLS in 
diabetic neuropathy yielded conflicting results with a 
prevalence rate ranging from 8.8 to 27%, not significantly 
different even from controls in some studies [11, 17-18]. 
Poor glycemic control with RLS may also impact the 
associated consequences of diabetes mellitus including 
sleep quality, sleep cycle alterations, fatigue, and 
depression [19]. Norma G et al reported that diabetic 
people at risk for RLS were at increased risk for obstructive 
sleep apnea and insomnia-sleep problems often 
reported in diabetes [19]. Montplasir et al reported 
significant association between RLS and Periodic Limb 
Movements during Sleep (PLMS) during sleep or while 
INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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awake [20]. However, there is paucity of local data in this 
regard. We hypothesized that patients with type 2 
diabetes mellitus will show a high frequency of RLS.  
Therefore, we sought to determine the frequency of RLS 
in subjects with type 2 diabetes mellitus and its associ-
ated factors especially sleep disturbances, daytime 
time functioning  and PLMS. with non-adherence to 
AEDs and help in taking possible measures to improve 
antiepileptic drug compliance and prevent conse-
quences of uncontrolled seizures. The prevalence of 
epilepsy in Pakistan is about 9.99/1000.
METHODS
Patient selection
For this study, 120 consecutive subjects with type 2 
diabetes mellitus who attended the diabetes clinic of 
Jinnah Medical Dental College Hospital, Karachi from 
July 2009 to July 2010 were recruited. Ethical approval 
for the study was taken from local ethics review 
committee of the hospital. The non-diabetic group 
consisted of 54 consecutive patients who attended the 
medical outpatient clinics for some seasonal illness 
during the study period with no sign/symptom of any 
chronic disease. We included all the subjects who were 
30 years old or above, irrespective of the gender. We 
excluded all the patients who were known to have (or 
were being treated for) anemia, chronic liver disease, 
thyroid dysfunction, uremia and non-diabetic polyneu-
ropathy. Similarly, pregnant women were excluded from 
the study as RLS is already expected to be more prevalent 
in this set of population. Patients who had a language 
barrier were also excluded to minimize the biases in 
clinical findings and ensure the authenticity of information. 
All the participants provided an informed consent.
General Protocol
Records were reviewed and patients were interviewed 
using a closed ended questionnaire regarding their 
demographic aspects, past medical history, family 
history and use of medications. In particular, we 
inquired about the clinical conditions which support 
RLS (such as iron-deficiency anemia, hypothyroidism, 
uremia, and rheumatoid arthritis) and about the drugs 
which could possibly worsen RLS symptoms 
(antidepressants or antipsychotics) or rather improve 
RLS symptoms (dopaminergic agents, benzodiazepines, 
and anticonvulsants such as gabapentin, carbamazepine, 
oxcarbazepine, and valproic acid). Moreover, both 
diabetic and non-diabetic subjects were specifically 
asked for: (1) disturbance of sleep (2) daytime sleepiness 
(3) daytime dysfunction; and (4) presence of PLMS. Sleep 
disturbance was defined as difficulty in falling asleep 
and awakening. Daytime sleepiness was assessed by 
Epworth Sleepiness Scale (ESS) which is a validated 
tool. A score of >10 was indicative of excessive 
daytime sleepiness. [13] Patients were considered to 
have daytime dysfunctioning when they have a subjective 
complain about it. Presence of PLMS as reported by the 
bed partner or close family member was ascertained as 
described in the literature i.e. periodic jerky movements 
causing flexion of the ankle, knee, or hip; occasionally 
accompanied by arousals from sleep, leading to sleep 
fragmentation and excessive daytime sleepiness [18]. 
RLS Protocol
In all the study subjects, a neurologist confirmed the 
presence of RLS using the criteria defined by the Inter-
national Restless Legs Syndrome Study Group (IRLSSG) 
[12]. Only the patients who fulfilled all 4 criteria were 
considered affected by RLS and were further asked 
about the frequency, duration and intensity of the 
symptoms. Presence of RLS symptoms in first-degree 
relatives was established in both diabetic and non-
diabetic subjects.
 
Laboratory Data
Laboratory data was obtained at the time of interview 
for complete blood count, creatinine, random and 
fasting blood glucose in all subjects and for serum 
ferritin and glycosylated hemoglobin (HbA1c) in 79 and 
152 subjects respectively.
Evaluation of polyneuropathy
Distal sensory function was examined bilaterally using 
Semmes-Weinstein (SW) filaments as recommended by 
the World Health Organization and International Diabetes 
Federation for screening peripheral neuropathy in 
diabetic subjects [21]. The dorsal surface of the foot and 
the heel was tested in a random manner on 10 prede-
termined sites [21-22] with the filament pressed perpen-
dicularly, for 1 second, and pressure enough to bend 
the filament. Patient’s response was noted on the basis 
of yes/no option. Those patients who were able to 
perceive at less than 6 points were considered to have 
neuropathy [21].
Statistical Analysis
Sample size estimation: A sample size of at least 175 
was required to estimate the proportion of RLS among 
diabetics, however there is no literature available in our 
region assuming 10-15% prevalence in the regional 
population along with 80 percent power, 0.05 significance 
level, 5 percent bond on error, and 5% adjustment for 
non-response rate. As previously reported by Rozina S 
et al, RLS was seen in around 10% of the general 
population.[7] Data was entered and analyzed using 
Statistical Package Social Sciences (SPSS) version 
19.0. Initially descriptive statistics and frequencies and 
proportions were generated. Continuous variables were 
analyzed by t– test and categorical by chi-square or 
Fisher exact, where appropriate.  Later stepwise multi-
variable logistic regression was done to identify factors 
related with RLS among diabetics.
RESULTS
General characteristics of the diabetic and non-diabetic 
subjects are presented in Table 1. Diabetic subjects 
were comparably elder as compared to the non-diabetic 
subjects. Also, there was a slight preponderance of 
male gender in the diabetic subjects. Presence of sleep 
disorders, PLMS and RLS, family history of diabetes 
mellitus and RLS, and higher glycemic indices were 
significantly frequent among diabetic subjects. Only 
34% of the diabetic subjects had a value of HbA1c < 
7%. Most of the patients (94%) were taking oral hypo-
glycemic agents, the rest were on insulin therapy. PLMS 
were reported by 32 (26.7%) diabetics’ subjects only; 
of whom 21(65%) subjects had RLS. Sixty seven of the 
120 subjects with type 2 diabetes mellitus (55.8%) 
were diagnosed as having RLS (p < 0.05). Among 
these subjects, 28/67 (41.8%) had diabetes for < 
5years, 26/67 (38.8%) for >10 years, while the rest of 
them (13/67; 19.4%) had diabetes for 5-10 years. The 
laboratory parameters of RLS subjects revealed higher 
values for the glycemic indices including random and 
fasting blood sugar; and HbA1c level (Table 2). Among 
RLS subjects, none reported a positive family history of 
any sleep disorder which was in contrast to 4 (3.7%) of 
the non-RLS subjects. Among the subjects who did not 
fulfill the RLS criteria (n;53) the individual RLS like 
complains were evaluated. Unpleasant sensation in the 
legs with urge to move them was reported in 42.8%, 
worsening during inactivity or rest in 25.6%, relieved by 
activity in 18.1% while nocturnal worsening was 
reported by 22.4% of non- RLS subjects. Among RLS 
subjects, the majority of the subjects were using over-
the-counter analgesics (59/67; 88%). In univariate 
analysis, female gender, increasing age, clinical 
evidence of neuropathy, disturbance of sleep, daytime 
sleepiness, and impaired daytime functioning appeared 
as predictors of presence of RLS (Table 3). However, 
only advancing age, impaired daytime functioning and 
clinical evidence of neuropathy appeared as the predictors 
of RLS in multivariate analysis (Table 4). The multivariable 
analysis showed that having impaired daytime functioning 
due to sleep disorder was 47 times more associated 
with RLS adjusting for other covariates (adjusted Odds 
Ratio (OR) 47; 95% CI 10.3-217). Likewise, odds of 
having RLS among those with an evidence of neuropathy 
were 15 times more than those without neuropathy 
(adjusted OR= 15, 95% CI = 3.8-58). Every one year 
increase in age showed a 20% increase in risk of having 
RLS after adjusting other variables (Adjusted OR= 1.2, 
95% CI = 1.1-1.3). Interestingly, despite the high 
prevalence reported from the subcontinent, none of the 
non-diabetic subject suffered from either RLS or PLMS. 
To our surprise, none of the subjects who were 
diagnosed as RLS was ever asked by their physician for 
symptoms or diagnosis of RLS prior to this study.
DISCUSSION
The reported prevalence of RLS in general population by 
Western countries ranges between 5-15% [23] whereas 
data from Asian countries has reported a lower prevalence 
(1.5% in Japan [24], 1% in Singapore [25], 3.19% in 
Turkey [26]). Recently, higher prevalence rate i.e. 9.71% 
[27] has been reported by a Turkish study but their study 
population included subjects aged 40 years and above. 
Population based studies have found higher prevalence 
rates of RLS among subjects with advanced age, 
increased body mass index, smoking and diabetes 
mellitus [28,29]. Such varied differences in ranges might 
be due to the reason that some have heterogeneity in 
study design, study population and sample size. With 
no local data in this regard from Pakistan, this is the 
first Pakistani study confirming significant association 
between RLS and type 2 diabetes mellitus. The 
frequency of RLS in our diabetic subjects (55.8%) is 
significantly higher than compared to the international 
literature. Merlino et al diagnosed the RLS on the basis 
of International RLS Study Group criteria and reported a 
prevalence of 17.7% in their study population of 
diabetic subjects [4]. Lopes et al reported a comparatively 
higher frequency of RLS in 27% of the diabetic subjects 
[18], which is still lower than the frequency we found in 
our cohort. Peripheral neuropathy has been postulated 
to be associated with the pathogenesis of RLS. Qu S 
and Jensen et al have hypothesized that RLS in diabetic 
subjects could be due to the concurrence of decreased 
inhibitory dopaminergic control on the dorsal horns of 
the spinal gray matter [30-31] with the excitatory nociceptive 
inputs due to the peripheral neuropathy [32]. Various 
clinical studies have reported a significant association 
between RLS and polyneuropathy [8,33,34]. However, 
Skomro et al reported an insignificant association 
between RLS and diabetic polyneuropathy (p-value: 
0.78) [11]. In our study, odds of having RLS among 
those with an evidence of neuropathy were 15 times 
more than those without neuropathy (adjusted OR= 
15, 95% CI = 3.8-58). Diabetic subjects who were 
affected by RLS described their symptoms as an urge to 
move their limbs while those who had clinical evidence 
of neuropathy described their symptoms as pain, 
electric, or burning (pricking) sensations. This is in 
accordance with previous results shown by Winkelmann 
et al and Merlino et al [4, 35] A part from neuropathy, iron 
deficiency anemia is a well known contributor towards 
symptomatic form of RLS.[10] Our iron studies have 
shown insignificant association between RLS/diabetic+ 
subjects and iron studies which was in accordance with 
results demonstrated by previous studies [4, 11] thus 
further  pointing towards a lack of association. However, 
more clinic-pathological studies are needed to further 
verify this hypothesis. Significant number of RLS 
patients in our study reported sleep disturbance with 
daytime sleepiness and impaired daytime functioning 
which was consistent with results from previous studies 
on diabetic subjects. We found sleep disturbance to be 
associated with polyneuropathy and RLS. Similar correlation 
has been demonstrated by previous other studies [11, 14, 
36-37]. Our study has shown a significant association 
between RLS and PLMS as the majority of the PLMS 
patients were suffering from RLS too. In addition to 
diabetes, studies have also reported a significant association 
of RLS with diseases such as hypertension which could 
be due to concomitant sleep disturbances in such 
patients [38-41]. Advancing age and polyneuropathy have 
been shown to be associated with an increased preva-
lence of RLS [18,28]. The multivariate analysis established 
this association in our subjects as well (Table 2). A large 
number of our non-RLS subjects were those who 
suffered from a combination of symptoms included in 
the IRLSSG diagnostic criteria but they however, failed 
to meet all 4 criteria to be defined as RLS. We assume 
that these patients might be a potential case of RLS 
and may be defined as possible or probable RLS later. 
We propose that this criterion might be revised to take 
into account these large number of potential RLS 
patients so that early diagnosis and thus early identification 
of risk factors and their treatment might help them to 
enjoy a better quality of life. Interestingly, none of the 
non-diabetic subject suffered from either RLS or PLMS. 
Most importantly, none of our RLS subjects were ever 
asked by their physician for symptoms or diagnosis of 
RLS prior to this study. This may be because of the poor 
awareness of RLS among physicians as well.
LIMITATIONS
Our study was a single centered study so results cannot 
be generalized over the whole population. Ideally the 
patients who are suspected to have neuropathy by SW 
monofilament testing should undergo a standard nerve 
conduction study –the gold standard for the confirmation 
of neuropathy. Also, PLMS needs to be diagnosed with 
standard polysomnography.
STRENGTHS
This will be the first study from Pakistan which has 
addressed the frequency of RLS and its association with 
diabetes mellitus. Therefore, the results of this study 
are important as they provide the insight into this 
important and potentially treatable medical disorder in 
the local perspective. In addition to results shown 
above, our study has also shown the utility of SW mono-
filament in screening for the presence of sensory 
neuropathy. This is important in view of World Health 
Organization (WHO) report which has stated that 32% 
of the Pakistani population lives below poverty line. 
Hence, nerve conduction study (NCS/EMG) is not an 
economically pliable tool for the diagnosis of sensory 
neuropathy in our general community. So, SW filament 
utility has again come up in our study as a useful tool.
CONCLUSION
RLS is a common problem among patients with type 2 
diabetes mellitus and is associated with increasing age, 
peripheral neuropathy and impaired day time functioning. 
Its diagnosis is often delayed because of poor recognition 
by the physicians. Early diagnosis may result in 
improved quality of life of these patients. Considering a 
substantial number of subjects with one or more symptoms 
suggestive of RLS in the non-RLS group, further studies 
with larger sample size are needed to establish the 
importance of individual symptoms to guide the investi-
gation and the therapy in this sub-set of patients.
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INTRODUCTION
Restless legs syndrome (RLS) is a chronic sensorimotor 
disorder [1-4]. RLS can either be primary or secondary. 
Primary or idiopathic RLS, diagnosed when clinical 
conditions responsible for secondary forms are 
excluded by laboratory and clinical examinations, 
accounts for about 70 -80% of all RLS cases [1,5]. 
Among secondary or symptomatic forms, several conditions 
such as iron deficiency anemia, uremia, pregnancy, 
polyneuropathy and type 2 diabetes mellitus have been 
implicated in association with RLS [6-11]. RLS has 
recently been characterized by The International Restless 
Legs Syndrome Study Group (IRLSSG) as a clinical 
syndrome presenting as a combination of intense desire 
to move the limbs associated with paresthesias/dysesthesias; 
motor restlessness; exacerbation of symptoms with 
inactivity and relief by activity; and a nocturnal worsening 
in the symptom [12]. According to the Western data, it 
affects approximately 7-11.5% of the adult population 
and is found to be higher in women than in men. The 
intensity of sensory and motor symptoms generally 
tends to increase with advancing age. Alcoholics, smokers 
and selective serotonin reuptake inhibitor (SSRI) users 
as well as patients suffering from neuropathy are more 
likely to have RLS [2, 13-16]. Diabetes mellitus is a lifelong 
disease and a common cause of sensorimotor polyneu-
ropathy [13]. However, previous studies on RLS in 
diabetic neuropathy yielded conflicting results with a 
prevalence rate ranging from 8.8 to 27%, not significantly 
different even from controls in some studies [11, 17-18]. 
Poor glycemic control with RLS may also impact the 
associated consequences of diabetes mellitus including 
sleep quality, sleep cycle alterations, fatigue, and 
depression [19]. Norma G et al reported that diabetic 
people at risk for RLS were at increased risk for obstructive 
sleep apnea and insomnia-sleep problems often 
reported in diabetes [19]. Montplasir et al reported 
significant association between RLS and Periodic Limb 
Movements during Sleep (PLMS) during sleep or while 
INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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awake [20]. However, there is paucity of local data in this 
regard. We hypothesized that patients with type 2 
diabetes mellitus will show a high frequency of RLS.  
Therefore, we sought to determine the frequency of RLS 
in subjects with type 2 diabetes mellitus and its associ-
ated factors especially sleep disturbances, daytime 
time functioning  and PLMS. with non-adherence to 
AEDs and help in taking possible measures to improve 
antiepileptic drug compliance and prevent conse-
quences of uncontrolled seizures. The prevalence of 
epilepsy in Pakistan is about 9.99/1000.
METHODS
Patient selection
For this study, 120 consecutive subjects with type 2 
diabetes mellitus who attended the diabetes clinic of 
Jinnah Medical Dental College Hospital, Karachi from 
July 2009 to July 2010 were recruited. Ethical approval 
for the study was taken from local ethics review 
committee of the hospital. The non-diabetic group 
consisted of 54 consecutive patients who attended the 
medical outpatient clinics for some seasonal illness 
during the study period with no sign/symptom of any 
chronic disease. We included all the subjects who were 
30 years old or above, irrespective of the gender. We 
excluded all the patients who were known to have (or 
were being treated for) anemia, chronic liver disease, 
thyroid dysfunction, uremia and non-diabetic polyneu-
ropathy. Similarly, pregnant women were excluded from 
the study as RLS is already expected to be more prevalent 
in this set of population. Patients who had a language 
barrier were also excluded to minimize the biases in 
clinical findings and ensure the authenticity of information. 
All the participants provided an informed consent.
General Protocol
Records were reviewed and patients were interviewed 
using a closed ended questionnaire regarding their 
demographic aspects, past medical history, family 
history and use of medications. In particular, we 
inquired about the clinical conditions which support 
RLS (such as iron-deficiency anemia, hypothyroidism, 
uremia, and rheumatoid arthritis) and about the drugs 
which could possibly worsen RLS symptoms 
(antidepressants or antipsychotics) or rather improve 
RLS symptoms (dopaminergic agents, benzodiazepines, 
and anticonvulsants such as gabapentin, carbamazepine, 
oxcarbazepine, and valproic acid). Moreover, both 
diabetic and non-diabetic subjects were specifically 
asked for: (1) disturbance of sleep (2) daytime sleepiness 
(3) daytime dysfunction; and (4) presence of PLMS. Sleep 
disturbance was defined as difficulty in falling asleep 
and awakening. Daytime sleepiness was assessed by 
Epworth Sleepiness Scale (ESS) which is a validated 
tool. A score of >10 was indicative of excessive 
daytime sleepiness. [13] Patients were considered to 
have daytime dysfunctioning when they have a subjective 
complain about it. Presence of PLMS as reported by the 
bed partner or close family member was ascertained as 
described in the literature i.e. periodic jerky movements 
causing flexion of the ankle, knee, or hip; occasionally 
accompanied by arousals from sleep, leading to sleep 
fragmentation and excessive daytime sleepiness [18]. 
RLS Protocol
In all the study subjects, a neurologist confirmed the 
presence of RLS using the criteria defined by the Inter-
national Restless Legs Syndrome Study Group (IRLSSG) 
[12]. Only the patients who fulfilled all 4 criteria were 
considered affected by RLS and were further asked 
about the frequency, duration and intensity of the 
symptoms. Presence of RLS symptoms in first-degree 
relatives was established in both diabetic and non-
diabetic subjects.
 
Laboratory Data
Laboratory data was obtained at the time of interview 
for complete blood count, creatinine, random and 
fasting blood glucose in all subjects and for serum 
ferritin and glycosylated hemoglobin (HbA1c) in 79 and 
152 subjects respectively.
Evaluation of polyneuropathy
Distal sensory function was examined bilaterally using 
Semmes-Weinstein (SW) filaments as recommended by 
the World Health Organization and International Diabetes 
Federation for screening peripheral neuropathy in 
diabetic subjects [21]. The dorsal surface of the foot and 
the heel was tested in a random manner on 10 prede-
termined sites [21-22] with the filament pressed perpen-
dicularly, for 1 second, and pressure enough to bend 
the filament. Patient’s response was noted on the basis 
of yes/no option. Those patients who were able to 
perceive at less than 6 points were considered to have 
neuropathy [21].
Statistical Analysis
Sample size estimation: A sample size of at least 175 
was required to estimate the proportion of RLS among 
diabetics, however there is no literature available in our 
region assuming 10-15% prevalence in the regional 
population along with 80 percent power, 0.05 significance 
level, 5 percent bond on error, and 5% adjustment for 
non-response rate. As previously reported by Rozina S 
et al, RLS was seen in around 10% of the general 
population.[7] Data was entered and analyzed using 
Statistical Package Social Sciences (SPSS) version 
19.0. Initially descriptive statistics and frequencies and 
proportions were generated. Continuous variables were 
analyzed by t– test and categorical by chi-square or 
Fisher exact, where appropriate.  Later stepwise multi-
variable logistic regression was done to identify factors 
related with RLS among diabetics.
RESULTS
General characteristics of the diabetic and non-diabetic 
subjects are presented in Table 1. Diabetic subjects 
were comparably elder as compared to the non-diabetic 
subjects. Also, there was a slight preponderance of 
male gender in the diabetic subjects. Presence of sleep 
disorders, PLMS and RLS, family history of diabetes 
mellitus and RLS, and higher glycemic indices were 
significantly frequent among diabetic subjects. Only 
34% of the diabetic subjects had a value of HbA1c < 
7%. Most of the patients (94%) were taking oral hypo-
glycemic agents, the rest were on insulin therapy. PLMS 
were reported by 32 (26.7%) diabetics’ subjects only; 
of whom 21(65%) subjects had RLS. Sixty seven of the 
120 subjects with type 2 diabetes mellitus (55.8%) 
were diagnosed as having RLS (p < 0.05). Among 
these subjects, 28/67 (41.8%) had diabetes for < 
5years, 26/67 (38.8%) for >10 years, while the rest of 
them (13/67; 19.4%) had diabetes for 5-10 years. The 
laboratory parameters of RLS subjects revealed higher 
values for the glycemic indices including random and 
fasting blood sugar; and HbA1c level (Table 2). Among 
RLS subjects, none reported a positive family history of 
any sleep disorder which was in contrast to 4 (3.7%) of 
the non-RLS subjects. Among the subjects who did not 
fulfill the RLS criteria (n;53) the individual RLS like 
complains were evaluated. Unpleasant sensation in the 
legs with urge to move them was reported in 42.8%, 
worsening during inactivity or rest in 25.6%, relieved by 
activity in 18.1% while nocturnal worsening was 
reported by 22.4% of non- RLS subjects. Among RLS 
subjects, the majority of the subjects were using over-
the-counter analgesics (59/67; 88%). In univariate 
analysis, female gender, increasing age, clinical 
evidence of neuropathy, disturbance of sleep, daytime 
sleepiness, and impaired daytime functioning appeared 
as predictors of presence of RLS (Table 3). However, 
only advancing age, impaired daytime functioning and 
clinical evidence of neuropathy appeared as the predictors 
of RLS in multivariate analysis (Table 4). The multivariable 
analysis showed that having impaired daytime functioning 
due to sleep disorder was 47 times more associated 
with RLS adjusting for other covariates (adjusted Odds 
Ratio (OR) 47; 95% CI 10.3-217). Likewise, odds of 
having RLS among those with an evidence of neuropathy 
were 15 times more than those without neuropathy 
(adjusted OR= 15, 95% CI = 3.8-58). Every one year 
increase in age showed a 20% increase in risk of having 
RLS after adjusting other variables (Adjusted OR= 1.2, 
95% CI = 1.1-1.3). Interestingly, despite the high 
prevalence reported from the subcontinent, none of the 
non-diabetic subject suffered from either RLS or PLMS. 
To our surprise, none of the subjects who were 
diagnosed as RLS was ever asked by their physician for 
symptoms or diagnosis of RLS prior to this study.
DISCUSSION
The reported prevalence of RLS in general population by 
Western countries ranges between 5-15% [23] whereas 
data from Asian countries has reported a lower prevalence 
(1.5% in Japan [24], 1% in Singapore [25], 3.19% in 
Turkey [26]). Recently, higher prevalence rate i.e. 9.71% 
[27] has been reported by a Turkish study but their study 
population included subjects aged 40 years and above. 
Population based studies have found higher prevalence 
rates of RLS among subjects with advanced age, 
increased body mass index, smoking and diabetes 
mellitus [28,29]. Such varied differences in ranges might 
be due to the reason that some have heterogeneity in 
study design, study population and sample size. With 
no local data in this regard from Pakistan, this is the 
first Pakistani study confirming significant association 
between RLS and type 2 diabetes mellitus. The 
frequency of RLS in our diabetic subjects (55.8%) is 
significantly higher than compared to the international 
literature. Merlino et al diagnosed the RLS on the basis 
of International RLS Study Group criteria and reported a 
prevalence of 17.7% in their study population of 
diabetic subjects [4]. Lopes et al reported a comparatively 
higher frequency of RLS in 27% of the diabetic subjects 
[18], which is still lower than the frequency we found in 
our cohort. Peripheral neuropathy has been postulated 
to be associated with the pathogenesis of RLS. Qu S 
and Jensen et al have hypothesized that RLS in diabetic 
subjects could be due to the concurrence of decreased 
inhibitory dopaminergic control on the dorsal horns of 
the spinal gray matter [30-31] with the excitatory nociceptive 
inputs due to the peripheral neuropathy [32]. Various 
clinical studies have reported a significant association 
between RLS and polyneuropathy [8,33,34]. However, 
Skomro et al reported an insignificant association 
between RLS and diabetic polyneuropathy (p-value: 
0.78) [11]. In our study, odds of having RLS among 
those with an evidence of neuropathy were 15 times 
more than those without neuropathy (adjusted OR= 
15, 95% CI = 3.8-58). Diabetic subjects who were 
affected by RLS described their symptoms as an urge to 
move their limbs while those who had clinical evidence 
of neuropathy described their symptoms as pain, 
electric, or burning (pricking) sensations. This is in 
accordance with previous results shown by Winkelmann 
et al and Merlino et al [4, 35] A part from neuropathy, iron 
deficiency anemia is a well known contributor towards 
symptomatic form of RLS.[10] Our iron studies have 
shown insignificant association between RLS/diabetic+ 
subjects and iron studies which was in accordance with 
results demonstrated by previous studies [4, 11] thus 
further  pointing towards a lack of association. However, 
more clinic-pathological studies are needed to further 
verify this hypothesis. Significant number of RLS 
patients in our study reported sleep disturbance with 
daytime sleepiness and impaired daytime functioning 
which was consistent with results from previous studies 
on diabetic subjects. We found sleep disturbance to be 
associated with polyneuropathy and RLS. Similar correlation 
has been demonstrated by previous other studies [11, 14, 
36-37]. Our study has shown a significant association 
between RLS and PLMS as the majority of the PLMS 
patients were suffering from RLS too. In addition to 
diabetes, studies have also reported a significant association 
of RLS with diseases such as hypertension which could 
be due to concomitant sleep disturbances in such 
patients [38-41]. Advancing age and polyneuropathy have 
been shown to be associated with an increased preva-
lence of RLS [18,28]. The multivariate analysis established 
this association in our subjects as well (Table 2). A large 
number of our non-RLS subjects were those who 
suffered from a combination of symptoms included in 
the IRLSSG diagnostic criteria but they however, failed 
to meet all 4 criteria to be defined as RLS. We assume 
that these patients might be a potential case of RLS 
and may be defined as possible or probable RLS later. 
We propose that this criterion might be revised to take 
into account these large number of potential RLS 
patients so that early diagnosis and thus early identification 
of risk factors and their treatment might help them to 
enjoy a better quality of life. Interestingly, none of the 
non-diabetic subject suffered from either RLS or PLMS. 
Most importantly, none of our RLS subjects were ever 
asked by their physician for symptoms or diagnosis of 
RLS prior to this study. This may be because of the poor 
awareness of RLS among physicians as well.
LIMITATIONS
Our study was a single centered study so results cannot 
be generalized over the whole population. Ideally the 
patients who are suspected to have neuropathy by SW 
monofilament testing should undergo a standard nerve 
conduction study –the gold standard for the confirmation 
of neuropathy. Also, PLMS needs to be diagnosed with 
standard polysomnography.
STRENGTHS
This will be the first study from Pakistan which has 
addressed the frequency of RLS and its association with 
diabetes mellitus. Therefore, the results of this study 
are important as they provide the insight into this 
important and potentially treatable medical disorder in 
the local perspective. In addition to results shown 
above, our study has also shown the utility of SW mono-
filament in screening for the presence of sensory 
neuropathy. This is important in view of World Health 
Organization (WHO) report which has stated that 32% 
of the Pakistani population lives below poverty line. 
Hence, nerve conduction study (NCS/EMG) is not an 
economically pliable tool for the diagnosis of sensory 
neuropathy in our general community. So, SW filament 
utility has again come up in our study as a useful tool.
CONCLUSION
RLS is a common problem among patients with type 2 
diabetes mellitus and is associated with increasing age, 
peripheral neuropathy and impaired day time functioning. 
Its diagnosis is often delayed because of poor recognition 
by the physicians. Early diagnosis may result in 
improved quality of life of these patients. Considering a 
substantial number of subjects with one or more symptoms 
suggestive of RLS in the non-RLS group, further studies 
with larger sample size are needed to establish the 
importance of individual symptoms to guide the investi-
gation and the therapy in this sub-set of patients.
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INTRODUCTION
Restless legs syndrome (RLS) is a chronic sensorimotor 
disorder [1-4]. RLS can either be primary or secondary. 
Primary or idiopathic RLS, diagnosed when clinical 
conditions responsible for secondary forms are 
excluded by laboratory and clinical examinations, 
accounts for about 70 -80% of all RLS cases [1,5]. 
Among secondary or symptomatic forms, several conditions 
such as iron deficiency anemia, uremia, pregnancy, 
polyneuropathy and type 2 diabetes mellitus have been 
implicated in association with RLS [6-11]. RLS has 
recently been characterized by The International Restless 
Legs Syndrome Study Group (IRLSSG) as a clinical 
syndrome presenting as a combination of intense desire 
to move the limbs associated with paresthesias/dysesthesias; 
motor restlessness; exacerbation of symptoms with 
inactivity and relief by activity; and a nocturnal worsening 
in the symptom [12]. According to the Western data, it 
affects approximately 7-11.5% of the adult population 
and is found to be higher in women than in men. The 
intensity of sensory and motor symptoms generally 
tends to increase with advancing age. Alcoholics, smokers 
and selective serotonin reuptake inhibitor (SSRI) users 
as well as patients suffering from neuropathy are more 
likely to have RLS [2, 13-16]. Diabetes mellitus is a lifelong 
disease and a common cause of sensorimotor polyneu-
ropathy [13]. However, previous studies on RLS in 
diabetic neuropathy yielded conflicting results with a 
prevalence rate ranging from 8.8 to 27%, not significantly 
different even from controls in some studies [11, 17-18]. 
Poor glycemic control with RLS may also impact the 
associated consequences of diabetes mellitus including 
sleep quality, sleep cycle alterations, fatigue, and 
depression [19]. Norma G et al reported that diabetic 
people at risk for RLS were at increased risk for obstructive 
sleep apnea and insomnia-sleep problems often 
reported in diabetes [19]. Montplasir et al reported 
significant association between RLS and Periodic Limb 
Movements during Sleep (PLMS) during sleep or while 
INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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awake [20]. However, there is paucity of local data in this 
regard. We hypothesized that patients with type 2 
diabetes mellitus will show a high frequency of RLS.  
Therefore, we sought to determine the frequency of RLS 
in subjects with type 2 diabetes mellitus and its associ-
ated factors especially sleep disturbances, daytime 
time functioning  and PLMS. with non-adherence to 
AEDs and help in taking possible measures to improve 
antiepileptic drug compliance and prevent conse-
quences of uncontrolled seizures. The prevalence of 
epilepsy in Pakistan is about 9.99/1000.
METHODS
Patient selection
For this study, 120 consecutive subjects with type 2 
diabetes mellitus who attended the diabetes clinic of 
Jinnah Medical Dental College Hospital, Karachi from 
July 2009 to July 2010 were recruited. Ethical approval 
for the study was taken from local ethics review 
committee of the hospital. The non-diabetic group 
consisted of 54 consecutive patients who attended the 
medical outpatient clinics for some seasonal illness 
during the study period with no sign/symptom of any 
chronic disease. We included all the subjects who were 
30 years old or above, irrespective of the gender. We 
excluded all the patients who were known to have (or 
were being treated for) anemia, chronic liver disease, 
thyroid dysfunction, uremia and non-diabetic polyneu-
ropathy. Similarly, pregnant women were excluded from 
the study as RLS is already expected to be more prevalent 
in this set of population. Patients who had a language 
barrier were also excluded to minimize the biases in 
clinical findings and ensure the authenticity of information. 
All the participants provided an informed consent.
General Protocol
Records were reviewed and patients were interviewed 
using a closed ended questionnaire regarding their 
demographic aspects, past medical history, family 
history and use of medications. In particular, we 
inquired about the clinical conditions which support 
RLS (such as iron-deficiency anemia, hypothyroidism, 
uremia, and rheumatoid arthritis) and about the drugs 
which could possibly worsen RLS symptoms 
(antidepressants or antipsychotics) or rather improve 
RLS symptoms (dopaminergic agents, benzodiazepines, 
and anticonvulsants such as gabapentin, carbamazepine, 
oxcarbazepine, and valproic acid). Moreover, both 
diabetic and non-diabetic subjects were specifically 
asked for: (1) disturbance of sleep (2) daytime sleepiness 
(3) daytime dysfunction; and (4) presence of PLMS. Sleep 
disturbance was defined as difficulty in falling asleep 
and awakening. Daytime sleepiness was assessed by 
Epworth Sleepiness Scale (ESS) which is a validated 
tool. A score of >10 was indicative of excessive 
daytime sleepiness. [13] Patients were considered to 
have daytime dysfunctioning when they have a subjective 
complain about it. Presence of PLMS as reported by the 
bed partner or close family member was ascertained as 
described in the literature i.e. periodic jerky movements 
causing flexion of the ankle, knee, or hip; occasionally 
accompanied by arousals from sleep, leading to sleep 
fragmentation and excessive daytime sleepiness [18]. 
RLS Protocol
In all the study subjects, a neurologist confirmed the 
presence of RLS using the criteria defined by the Inter-
national Restless Legs Syndrome Study Group (IRLSSG) 
[12]. Only the patients who fulfilled all 4 criteria were 
considered affected by RLS and were further asked 
about the frequency, duration and intensity of the 
symptoms. Presence of RLS symptoms in first-degree 
relatives was established in both diabetic and non-
diabetic subjects.
 
Laboratory Data
Laboratory data was obtained at the time of interview 
for complete blood count, creatinine, random and 
fasting blood glucose in all subjects and for serum 
ferritin and glycosylated hemoglobin (HbA1c) in 79 and 
152 subjects respectively.
Evaluation of polyneuropathy
Distal sensory function was examined bilaterally using 
Semmes-Weinstein (SW) filaments as recommended by 
the World Health Organization and International Diabetes 
Federation for screening peripheral neuropathy in 
diabetic subjects [21]. The dorsal surface of the foot and 
the heel was tested in a random manner on 10 prede-
termined sites [21-22] with the filament pressed perpen-
dicularly, for 1 second, and pressure enough to bend 
the filament. Patient’s response was noted on the basis 
of yes/no option. Those patients who were able to 
perceive at less than 6 points were considered to have 
neuropathy [21].
Statistical Analysis
Sample size estimation: A sample size of at least 175 
was required to estimate the proportion of RLS among 
diabetics, however there is no literature available in our 
region assuming 10-15% prevalence in the regional 
population along with 80 percent power, 0.05 significance 
level, 5 percent bond on error, and 5% adjustment for 
non-response rate. As previously reported by Rozina S 
et al, RLS was seen in around 10% of the general 
population.[7] Data was entered and analyzed using 
Statistical Package Social Sciences (SPSS) version 
19.0. Initially descriptive statistics and frequencies and 
proportions were generated. Continuous variables were 
analyzed by t– test and categorical by chi-square or 
Fisher exact, where appropriate.  Later stepwise multi-
variable logistic regression was done to identify factors 
related with RLS among diabetics.
RESULTS
General characteristics of the diabetic and non-diabetic 
subjects are presented in Table 1. Diabetic subjects 
were comparably elder as compared to the non-diabetic 
subjects. Also, there was a slight preponderance of 
male gender in the diabetic subjects. Presence of sleep 
disorders, PLMS and RLS, family history of diabetes 
mellitus and RLS, and higher glycemic indices were 
significantly frequent among diabetic subjects. Only 
34% of the diabetic subjects had a value of HbA1c < 
7%. Most of the patients (94%) were taking oral hypo-
glycemic agents, the rest were on insulin therapy. PLMS 
were reported by 32 (26.7%) diabetics’ subjects only; 
of whom 21(65%) subjects had RLS. Sixty seven of the 
120 subjects with type 2 diabetes mellitus (55.8%) 
were diagnosed as having RLS (p < 0.05). Among 
these subjects, 28/67 (41.8%) had diabetes for < 
5years, 26/67 (38.8%) for >10 years, while the rest of 
them (13/67; 19.4%) had diabetes for 5-10 years. The 
laboratory parameters of RLS subjects revealed higher 
values for the glycemic indices including random and 
fasting blood sugar; and HbA1c level (Table 2). Among 
RLS subjects, none reported a positive family history of 
any sleep disorder which was in contrast to 4 (3.7%) of 
the non-RLS subjects. Among the subjects who did not 
fulfill the RLS criteria (n;53) the individual RLS like 
complains were evaluated. Unpleasant sensation in the 
legs with urge to move them was reported in 42.8%, 
worsening during inactivity or rest in 25.6%, relieved by 
activity in 18.1% while nocturnal worsening was 
reported by 22.4% of non- RLS subjects. Among RLS 
subjects, the majority of the subjects were using over-
the-counter analgesics (59/67; 88%). In univariate 
analysis, female gender, increasing age, clinical 
evidence of neuropathy, disturbance of sleep, daytime 
sleepiness, and impaired daytime functioning appeared 
as predictors of presence of RLS (Table 3). However, 
only advancing age, impaired daytime functioning and 
clinical evidence of neuropathy appeared as the predictors 
of RLS in multivariate analysis (Table 4). The multivariable 
analysis showed that having impaired daytime functioning 
due to sleep disorder was 47 times more associated 
with RLS adjusting for other covariates (adjusted Odds 
Ratio (OR) 47; 95% CI 10.3-217). Likewise, odds of 
having RLS among those with an evidence of neuropathy 
were 15 times more than those without neuropathy 
(adjusted OR= 15, 95% CI = 3.8-58). Every one year 
increase in age showed a 20% increase in risk of having 
RLS after adjusting other variables (Adjusted OR= 1.2, 
95% CI = 1.1-1.3). Interestingly, despite the high 
prevalence reported from the subcontinent, none of the 
non-diabetic subject suffered from either RLS or PLMS. 
To our surprise, none of the subjects who were 
diagnosed as RLS was ever asked by their physician for 
symptoms or diagnosis of RLS prior to this study.
DISCUSSION
The reported prevalence of RLS in general population by 
Western countries ranges between 5-15% [23] whereas 
data from Asian countries has reported a lower prevalence 
(1.5% in Japan [24], 1% in Singapore [25], 3.19% in 
Turkey [26]). Recently, higher prevalence rate i.e. 9.71% 
[27] has been reported by a Turkish study but their study 
population included subjects aged 40 years and above. 
Population based studies have found higher prevalence 
rates of RLS among subjects with advanced age, 
increased body mass index, smoking and diabetes 
mellitus [28,29]. Such varied differences in ranges might 
be due to the reason that some have heterogeneity in 
study design, study population and sample size. With 
no local data in this regard from Pakistan, this is the 
first Pakistani study confirming significant association 
between RLS and type 2 diabetes mellitus. The 
frequency of RLS in our diabetic subjects (55.8%) is 
significantly higher than compared to the international 
literature. Merlino et al diagnosed the RLS on the basis 
of International RLS Study Group criteria and reported a 
prevalence of 17.7% in their study population of 
diabetic subjects [4]. Lopes et al reported a comparatively 
higher frequency of RLS in 27% of the diabetic subjects 
[18], which is still lower than the frequency we found in 
our cohort. Peripheral neuropathy has been postulated 
to be associated with the pathogenesis of RLS. Qu S 
and Jensen et al have hypothesized that RLS in diabetic 
subjects could be due to the concurrence of decreased 
inhibitory dopaminergic control on the dorsal horns of 
the spinal gray matter [30-31] with the excitatory nociceptive 
inputs due to the peripheral neuropathy [32]. Various 
clinical studies have reported a significant association 
between RLS and polyneuropathy [8,33,34]. However, 
Skomro et al reported an insignificant association 
between RLS and diabetic polyneuropathy (p-value: 
0.78) [11]. In our study, odds of having RLS among 
those with an evidence of neuropathy were 15 times 
more than those without neuropathy (adjusted OR= 
15, 95% CI = 3.8-58). Diabetic subjects who were 
affected by RLS described their symptoms as an urge to 
move their limbs while those who had clinical evidence 
of neuropathy described their symptoms as pain, 
electric, or burning (pricking) sensations. This is in 
accordance with previous results shown by Winkelmann 
et al and Merlino et al [4, 35] A part from neuropathy, iron 
deficiency anemia is a well known contributor towards 
symptomatic form of RLS.[10] Our iron studies have 
shown insignificant association between RLS/diabetic+ 
subjects and iron studies which was in accordance with 
results demonstrated by previous studies [4, 11] thus 
further  pointing towards a lack of association. However, 
more clinic-pathological studies are needed to further 
verify this hypothesis. Significant number of RLS 
patients in our study reported sleep disturbance with 
daytime sleepiness and impaired daytime functioning 
which was consistent with results from previous studies 
on diabetic subjects. We found sleep disturbance to be 
associated with polyneuropathy and RLS. Similar correlation 
has been demonstrated by previous other studies [11, 14, 
36-37]. Our study has shown a significant association 
between RLS and PLMS as the majority of the PLMS 
patients were suffering from RLS too. In addition to 
diabetes, studies have also reported a significant association 
of RLS with diseases such as hypertension which could 
be due to concomitant sleep disturbances in such 
patients [38-41]. Advancing age and polyneuropathy have 
been shown to be associated with an increased preva-
lence of RLS [18,28]. The multivariate analysis established 
this association in our subjects as well (Table 2). A large 
number of our non-RLS subjects were those who 
suffered from a combination of symptoms included in 
the IRLSSG diagnostic criteria but they however, failed 
to meet all 4 criteria to be defined as RLS. We assume 
that these patients might be a potential case of RLS 
and may be defined as possible or probable RLS later. 
We propose that this criterion might be revised to take 
into account these large number of potential RLS 
patients so that early diagnosis and thus early identification 
of risk factors and their treatment might help them to 
enjoy a better quality of life. Interestingly, none of the 
non-diabetic subject suffered from either RLS or PLMS. 
Most importantly, none of our RLS subjects were ever 
asked by their physician for symptoms or diagnosis of 
RLS prior to this study. This may be because of the poor 
awareness of RLS among physicians as well.
LIMITATIONS
Our study was a single centered study so results cannot 
be generalized over the whole population. Ideally the 
patients who are suspected to have neuropathy by SW 
monofilament testing should undergo a standard nerve 
conduction study –the gold standard for the confirmation 
of neuropathy. Also, PLMS needs to be diagnosed with 
standard polysomnography.
STRENGTHS
This will be the first study from Pakistan which has 
addressed the frequency of RLS and its association with 
diabetes mellitus. Therefore, the results of this study 
are important as they provide the insight into this 
important and potentially treatable medical disorder in 
the local perspective. In addition to results shown 
above, our study has also shown the utility of SW mono-
filament in screening for the presence of sensory 
neuropathy. This is important in view of World Health 
Organization (WHO) report which has stated that 32% 
of the Pakistani population lives below poverty line. 
Hence, nerve conduction study (NCS/EMG) is not an 
economically pliable tool for the diagnosis of sensory 
neuropathy in our general community. So, SW filament 
utility has again come up in our study as a useful tool.
CONCLUSION
RLS is a common problem among patients with type 2 
diabetes mellitus and is associated with increasing age, 
peripheral neuropathy and impaired day time functioning. 
Its diagnosis is often delayed because of poor recognition 
by the physicians. Early diagnosis may result in 
improved quality of life of these patients. Considering a 
substantial number of subjects with one or more symptoms 
suggestive of RLS in the non-RLS group, further studies 
with larger sample size are needed to establish the 
importance of individual symptoms to guide the investi-
gation and the therapy in this sub-set of patients.
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